Progress Annual Report 2009

The Michael J. Fox Foundation is dedicated to finding a cure for Parkinson’s disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinson’s today.

2 Letter From the CEO, Founder and Co-Founder

4 Scientific Progress Report High-priority Research Areas: the Science We’re Most Excited About Transforming Basic Discoveries Into Therapeutic Targets speeding Clinical Testing of New Interventions Mobilizing New Technologies and Tools in pd Therapeutic Development

18 Select List of Organizations with Active MJFF Awards in 2009

19 Select List of 2009 MJFF Workshops and Summit Meetings

20 2009 in Photos

22 2009 Donor Listing

40 Financial Highlights

Annual Report 2009 2 | MJFF ANNUAL REPORT 2009 Letter From the CEO, Founder and c0-Founder

Letter from the CEO, Founder and Co-Founder

In 2009, with the support of more than 56,000 individuals, corporations and foundations, The Michael J. Fox Foundation continued to invest where we saw potential to drive progress forward, pushing ourselves and our partners to ever-greater heights in pursuit of transformative treatments and a cure for Parkinson’s disease.

A gainst an uncertain economic backdrop, we funded As Canada’s Globe and Mail reported in September, our over $39 million in targeted Parkinson’s research — the aggressive, entrepreneurial approach to science lies at most we’ve ever funded in one year — bringing our total the heart of our mission to find a cure for Parkinson’s — research investments at year-end to nearly $170 million. and, in the process, to reshape the way medical research Yet those who know us know our core belief is that ending gets done. 2009 highlights include: Parkinson’s is not merely about spending more money, n Investing over $11 million in biomarker development but about spending that money with impact. Last year (bringing total funding in this area to over $25 million) we expanded our emphasis on critical research tools and and laying the groundwork to sponsor the Parkinson’s patients’ unmet needs while continuing to drive key next Progression Markers Initiative (PPMI), a landmark steps on top therapeutic targets. (Turn the page to read biomarker study launching in 2010. (While PPMI isn’t more about our high-priority research areas, the science covered in this report, you can learn more about it at we believe is closest or most critical to practical impact michaeljfox.org/PPMI.) on patients’ lives.) n Allocating over $3 million to pre-clinical models, Sitting at the hub of global PD research, our job is to act including a grant to speed a cutting-edge gene knockout urgently and strategically to dismantle roadblocks and technology into Parkinson’s therapeutic development streamline the path to a cure. We talk — and listen — within months of its advent. The technology was later to the world’s most prominent Parkinson’s scientists from named one of the top 10 scientific innovations of the year academic and industry labs about what they need and by The Scientist. where new opportunities lie. Our staff, which includes both scientific PhDs and business-trained project n Initiating a $1-million clinical trial to establish a managers, continually surveys a wide and complex field framework for the development of effective treatments in order to prioritize the projects most needed to accelerate for dyskinesia, the debilitating side effect of long-term new therapies. We work to see the big picture, then invest dopamine replacement therapy. our capital with one return in mind: speeding scientific n With lead support from The Edmond J. Safra Foundation, solutions to the nearly five million people living with awarding $2 million to drive development of treatment Parkinson’s worldwide. approaches for postural instability and gait disorder Letter From the CEO, Founder and c0-Founder MJFF ANNUAL REPORT 2009 | 3

(PIGD), a troubling constellation of symptoms that are from the critical perspective of those living with the disease. poorly understood and respond inconsistently or not at all Our new Leadership Council is made up of generous to dopamine replacement therapies. advisors who provide leadership financial support and strategic insight about how we can more effectively engage n With lead support from the Brin Wojcicki Foundation, new audiences to advance progress. And Team Fox, our executing an integrated, multi-million-dollar strategy to grassroots fundraising network, continued to inspire and advance biological understanding of LRRK2, the single unite communities across the country in passionate greatest known genetic contributor to Parkinson’s disease, pursuit of a cure. while simultaneously laying the groundwork for effective LRRK2 clinical trials in the future. Your dedication allows us to keep taking the risks that patients and their loved ones want taken in service of n Launching PD Online Research (pdonlineresearch.org), accelerating therapeutic breakthroughs. Our gratitude to you a Web-based platform for research professionals to is as clear and strong as our vision of a world without PD. engage daily on key research hurdles and new findings. So far, nearly 2,000 Parkinson’s researchers at all levels and from all over the world have become members.

We invite you to read more about these investments, Katie Hood and the potential we see in them to change the face of CEO Parkinson’s drug development, throughout this report and at michaeljfox.org.

Of course, effecting meaningful change in how new Michael J. Fox treatments are developed requires thoughtful strategies Founder for engaging not only scientists but also patients and caregivers, policymakers and other research funders. That’s why in 2009 we also focused on building and deepening our relationships and collaborations in every Deborah W. Brooks sector of the PD community. We chartered a Patient Co-Founder Council to provide input on our programmatic activities 4 | MJFF ANNUAL REPORT 2009 Scientific Progress Report

High-priority Research Areas: The Science We’re Most Excited About

While MJFF’s portfolio of investments includes up to 250 active grants spanning Parkinson’s therapeutic development, to achieve our mission of speeding the cure, we must strategically evaluate research hits and prioritize limited resources. This section provides an overview of our top priorities for funding and intellectual leadership. All Scientific P r o g r e s s are currently believed by our in-house research team and expert advisors to be critical R e p o r t areas of focus in our pursuit of transformative treatments for Parkinson’s in the shortest possible timeframe. You’ll find detailed stories about our work in these areas throughout this report.

Top Therapeutic Targets: Alpha-synuclein, LRRK2, Trophic Factors

Genetic targets Alpha-Synuclein and LRRK2. Though n First linked to PD in 2004, mutations in the LRRK2 only a small fraction of people with Parkinson’s carry gene are now believed to be the most common genetic mutations in PD-implicated genes, findings from genetic contribution to the disease. MJFF is driving a comprehensive studies open new avenues toward treatments that will strategy for advancing LRRK2 research. The goal is to shed benefit everyone with the disease. Two genetic targets, light on the gene’s biological role in PD while laying the alpha-synuclein and LRRK2, have risen to prominence groundwork for conclusive clinical trials. With lead support for their exceptional promise to provide new treatment from The Brin Wojcicki Foundation, MJFF has invested over approaches to Parkinson’s. $16 million in LRRK2 research to date.

n The gene known as alpha-synuclein produces a protein Trophic factors. Trophic factors (also known as that aggregates to form Lewy bodies, microscopic clumps neurotrophic factors or growth factors) are specialized that are the pathological hallmark of PD. Though alpha- proteins that protect and nurture neurons, including the synuclein’s precise role in PD remains unclear, growing dopamine neurons that die in Parkinson’s disease. While evidence supports the idea that decreasing its levels in clinical trials involving trophic factors have not yielded the brain could be one way to slow or stop Parkinson’s hoped-for results, The Michael J. Fox Foundation continues progression. MJFF has invested more than $32 million in to see great promise in trophic-based approaches to alpha-synuclein research to date. treating PD. The Foundation has invested over $20 million in trophic factor research to date, and in 2009 earmarked Cerebellum of a another $5 million under a 2010 LEAPS program to advance pre-clinical model state-of-the-art trophic factor therapies into the clinic. created to overexpress the protein alpha- synuclein (shown in green), helping scientists understand possible toxic effects of increased levels of the protein in the brain. High-Priority Research Areas MJFF ANNUAL REPORT 2009 | 5

Life and death of a neuron: Fluorescently labeled neurons show degenerative changes after expressing the mutant LRRK2 protein, the dominant genetic mutation that causes Parkinson’s in humans. Neurons are labeled red; their nuclei are blue; LRRK2 is green. At left is a cell expressing the normal version of LRRK2; the cell has a normal appearance. At right is a cell expressing the mutated form of LRRK2; it is shrunken and the nucleus is starting to die.

Patients’ Unmet Needs Critical Research Tools, New Technologies and Data Sharing Available treatments for Parkinson’s leave several Pre-clinical models. With about $13 million in investments, MJFF is a field leader in the troubling symptoms of the disease entirely development of improved models of PD that accurately mimic the human condition, allowing unaddressed. These include cognitive deficits researchers to test potential disease-modifying therapies. And to ensure that new and better and mood disorders, problems with posture and models get into scientists’ hands as quickly and efficiently as possible, we also are developing gait, and gastrointestinal (GI) problems such as practical, low-cost channels for worldwide distribution of these critical tools. constipation. Complications of current treatments, Biomarkers and clinical scales. To date we’ve invested nearly $29 million in biomarkers including dyskinesia (the excessive, uncontrollable and clinical scales, tools necessary for researchers to definitively assess treatment effects in movements that result from long-term dopamine clinical studies. In 2009 we launched an initiative to validate clinical scales used to measure replacement therapy), also diminish quality of life. changes in dyskinesia severity. We also laid the groundwork to sponsor a game-changing The Michael J. Fox Foundation is committed to longitudinal study, PPMI, launching in 2010, that will identify and verify PD biomarkers — providing the financial and intellectual leadership molecular or physiological characteristics that can be objectively measured and evaluated to required to drive treatments for patients’ unmet provide clearer outcomes from clinical trials and lower the hurdle to industry investment in PD. needs. Since its founding, MJFF has invested over Leveraging new technologies in PD. Research technologies emerge and evolve at a rapid pace. $11 million in dyskinesia research, including a We monitor these developments and apply funding to strategically leverage those that could major clinical trial launched in December 2009 to impact Parkinson’s science. In 2009 one such technology was named to The Scientist’s list of validate vitally needed clinical scales (see page 15). the top 10 scientific innovations of the year (see page 16). We have also funded millions of dollars in research toward alleviating untreated symptoms of PD — Data sharing. New technologies and systems could revolutionize the way researchers including developing the first pre-clinical models to communicate and share information. In addition to our ongoing activities to facilitate data mimic GI symptoms in Parkinson’s and, with lead exchange between and among academic and industry researchers, in 2009 we launched PD support from The Edmond J. Safra Foundation, our Online Research (PDOR) (www.pdonlineresearch.org). PDOR enables collaboration, instant 2009 $2-million initiative to drive treatments for communication and rapid problem-solving among scientists around the globe. Its goal is postural instability and gait disturbances. straightforward: enable quicker knowledge turns and faster progress toward therapeutic breakthroughs. By the end of the year, PD Online Research had almost 2,000 members from government, industry and academic sectors. 6 | MJFF ANNUAL REPORT 2009 Scientific Progress Report

Transforming Basic Discoveries Into Therapeutic Targets

Basic discoveries about the biological mechanisms of Parkinson’s disease are critical to the development of new therapies. Equally important, however, is a focused and deliberate effort to shepherd these discoveries through the complex process of therapeutic development and determine their real potential as breakthrough treatments. The stories on these pages Scientific P r o g r e s s illustrate MJFF’s unique role in partnering with researchers to put the most promising results R e p o r t on a fast track toward practical relevance in patients’ lives.

Going Viral: Could a Virus’s RNA Help Protect Neurons?

Molecular virologist John Sinclair, PhD, of the University of Cambridge wasn’t even think- ing about Parkinson’s when he discovered a previously unknown piece of viral RNA that keeps cells alive during infection. But his work on infectious disease elucidated an intrigu- ing possibility: Could viral RNA protect the neurons that die in PD, thus modifying disease progression, something no current treatment has been proven to do?

MJFF quickly came on board to help him find out. With fast funding under MJFF’s Rapid Response Innovation Awards, Dr. Sinclair successfully engineered a form of the viral RNA suitable for pre-clinical testing, and his team demonstrated its ability to protect neurons in parkinsonian models. The Foundation then provided follow-on funding for Dr. Sinclair’s

team to investigate the potential of the RNA complex to restore function to already- In the upper panels, the blue dopamine damaged neurons. neurons at left are exposed to a toxin and die, as shown by the red marker for “PD patients have lost a substantial percentage of their dopaminergic neurons by the time cell death at right. In the lower panels, of diagnosis,” says Dr. Sinclair. “So the real question is whether this complex can stop the dopamine neurons at left have been that process, preventing the disease from progressing further.” His group is also working treated with therapeutic RNA. As a result the cells do not die when exposed to the to identify the specific region of the viral RNA responsible for the protective effects. “The toxin, and no red cell death marker is more we can refine the RNA complex,” he explains, “the quicker we’ll be able to deliver a visible at right. therapy from bench to bedside.” Transforming BAsic Discoveries MJFF ANNUAL REPORT 2009 | 7

“You don’t gain much by keeping things under wraps. Actually getting different people with different viewpoints and different techniques to work together in an open fashion rapidly speeds up progress.” Patrick Lewis, University College London, MJFF LRRK2 Biology Consortium member

Sharing the Wealth (of Data): A Consortium Approach to Speed LRRK2-based Treatments

The LRRK2 gene holds tremendous promise as a The journal Nature Medicine wrote: “To foster therapeutic target for PD. Not only is it the single synergies moving forward, MJFF... established an most common contributor to genetic cases of the international consortium to focus on one of the disease, but it is a kinase — a type of cellular most promising candidate drug targets of the enzyme that is often highly druggable. Since neurodegenerative disease. Under the terms of the LRRK2 was first linked to Parkinson’s disease in two-year, $3.5-million grant design, members of Number of labs 30 2004, it has reinvigorated the field of Parkinson’s the consortium, which includes both academic and funded by MJFF in 2009 that had genetics and become the focus of intensive industry partners, will be compelled to share results never worked in investigation by research teams all over the world. and collaborate with one another on an ongoing basis to help accelerate therapeutic discoveries.” PD before MJFF’s research staff, in concert with the world’s leading experts in Parkinson’s genetics, has Nine different research teams are members of the $6.6 million moved quickly to integrate global LRRK2 efforts LRRK2 biology consortium. They are working to Amount of 2009 into a united and streamlined scientific movement help elucidate the functions of LRRK2 in the cell, research that will help minimize the timeline to practical identify other cellular proteins linked to LRRK2 funded by MJFF LRRK2-based therapies. In 2009 MJFF homed in (called substrates) and develop critical tools to in those labs on collaborative efforts to increase understanding drive further research. Several groups are using of LRRK2 biology, including convening a major complementary approaches to investigate related LRRK2 summit at the end of the year. The spirit questions around LRRK2. For example, three teams of collaboration was also extended to MJFF’s investigating substrates are using different types of search for investigative teams to join a LRRK2 tissues for each project, which will allow for faster biology consortium aiming to fast-forward efforts and more efficient cross-validation of any findings. to understand LRRK2 biology and target its “Getting people working together on LRRK2 research vulnerabilities. increases the pool of ideas and expertise to draw “This is a critical early moment in LRRK2 from, and it builds in a way to check your work with therapeutic development,” says Brian Fiske, others, which is unfortunately rare in science,” says PhD, associate director, team leader, Research Mark Cookson, PhD, a member of the MJFF Scientific Programs. “MJFF recognized the opportunity to Advisory Board and world-renowned expert on the transcend the disparate, one-off efforts that all cell biology of PD. “It will also help to keep people too often characterize scientific discovery and involved in the field, pushing forward to the next instead lead a strategic new approach that hits level that much faster. It’s an approach grounded in on multiple fronts simultaneously.” common sense.” 8 | MJFF ANNUAL REPORT 2009 Scientific Progress Report

Leverage: MJFF’s Industry Strategy Bears Fruit

With over 55 currently active industry collaborations at lower doses and reducing dyskinesias. With and more than 85 since MJFF’s inception, there positive outcomes in several relevant models of is little doubt of the Foundation’s commitment PD, principal investigator Gretchen Snyder, PhD, to partnering with biotech and pharmaceutical received supplemental funding in 2009 for what companies to speed treatments toward clinical will likely be the final pre-clinical work required $28.7 million testing and patients. But the greater goal of the before a Phase 1 clinical trial. 2009 MJFF Foundation’s “de-risking” strategy is to create Amicus Therapeutics of New Jersey also received funding to momentum and induce industry players to commit MJFF funding in 2006 to test an orally administered academic/ their own significant resources to pre-clinical small molecule with promise to decrease alpha- nonprofit teams and clinical Parkinson’s therapeutic development synuclein clumping, a hallmark of PD pathology. programs. When the MJFF-funded test of a chaperone in a pre- $10.2 million “We look for leverage everywhere,” says Debi Brooks, clinical model of PD resulted in intriguing efficacy 2009 MJFF MJFF co-founder. “That means identifying the and dosing data, Amicus launched an internal funding to projects where it’s a good bet that our investment PD drug development program. The company now industry teams of, say, a few hundred thousand dollars can create expects to complete advanced pre-clinical proof-of- a tipping point and increase the odds of a company concept studies in Parkinson’s disease during the investing millions down the line.” course of 2010 and to report additional data in the second half of the year. Throughout 2009, mounting evidence suggested that MJFF has made several good bets on industry “The support we received from The Michael J. Fox so far. Foundation was a key factor in our decision to commit to a Parkinson’s program,” says John F. For example, Intra-Cellular Therapies, Inc. has been Crowley, chairman and CEO of Amicus. “In 2010 funded by the Foundation since 2006 to develop we expect to make significant progress in our pre- a small-molecule drug to increase the potency clinical programs in Parkinson’s disease.” of levodopa, enabling relief of motor symptoms

With funding from The Michael J. Fox Foundation, Intra-Cellular Therapies Inc (ITI) is developing therapeutics to promote the intracellular response of brain cells to dopamine and restore the functions of dopamine that are lost in Parkinson’s disease. In the schematic at right, dopamine, released from nerve terminals, interacts with receptor proteins to produce intracellular changes in second messengers and protein kinases that control the activity of brain cells through effects on different classes of proteins, including neurotransmitter receptors, ion pumps, ion channels and transcription factors. Based on the work of Paul Greengard, Nobel Laureate in Physiology & Medicine (2000). Transforming BAsic Discoveries MJFF ANNUAL REPORT 2009 | 9

U pdate A Major Milestone for Glutamate and PD

MJFF’s 2008 annual report highlighted the work of LEAPS awardee P. Jeffrey Conn, PhD, who is pursuing an entirely new kind of symptomatic treatment for PD that would target glutamate — a molecule that, like dopamine, helps the brain send messages to the body. In 2009 Dr. Conn’s team at Vanderbilt University hit a major scientific milestone. “We discovered systemically active molecules and verified that they were beneficial in a pre-clinical model of PD,” says Dr. Conn. His team is now examining the effects of chronic dosing with these agents, testing their effects on subtle aspects of motor function in less severely parkinsonian models, and optimizing their drug-like characteristics. While there are no guarantees, if all goes well, the researchers could launch a clinical study in Parkinson’s patients by 2013.

Jeff Conn and Colleen Niswender

G-CSF: A New Trophic Factor Approaches the Clinic

In 2006 researchers Mathias Baehr, MD, and Jochen Weishaupt, MD, of University Hospital Goettingen in Germany approached MJFF to discuss a growth factor called G-CSF (granulocyte-colony stimulating factor). G-CSF, already approved by the U.S. Food and Drug Administration to treat complications of chemotherapy in cancer patients, was believed to reduce cell death in a pre-clinical model of Parkinson’s disease. The researchers were awarded funding under MJFF’s Target Validation program to gather additional data critical for advancing to clinical trials in PD patients, such as an effective dose range.

In results published in the Journal of Neurochemistry and BMC Neuroscience, and presented at the Foundation’s third annual PD Therapeutics Conference in September 2009, the researchers conclusively demonstrated that G-CSF was protecting neurons in a PD model; they also shed light on how it was achieving this beneficial effect. The researchers then ran extensive pre-clinical studies on an enhanced form of G-CSF called pegfilgrastim, which minimizes side effects and remains in the system longer.

Within months, MJFF granted follow-on funding for final pre-clinical studies in another relevant Parkinson’s model. “We will monitor the effects of pegfilgrastim over time, look for any side effects and precisely measure its ability to reduce cell loss and improve motor symptoms in pre-clinical models,” Protein structure of G-CSF says Dr. Weishaupt. “If all goes well, this will be the final step before a clinical study to test safety in Parkinson’s patients.” 10 | MJFF ANNUAL REPORT 2009 Scientific Progress Report

Speeding Clinical Testing of New Interventions

MJFF shares patients’ urgency to bring new and better Parkinson’s therapies to market as fast as possible. In prioritizing clinical trials, we emphasize proof- of-principle and first-in-human studies that can alter the risk profile of a given treatment. We also help assemble and organize teams, lend expertise to biotech Scientific P r o g r e s s and pharmaceutical companies testing or going deeper into PD waters, vet the R e p o r t Parkinson’s potential of drugs approved for other diseases, and sponsor trials where intellectual property or patent issues reduce companies’ incentive to get involved.

How Sweet It Is: A Diabetes Drug that Could Modify Progression of PD

When reports of the anti-inflammatory properties of the diabetes drug pioglitazone began to surface in the early 2000s, scientists saw an opportunity to translate these findings into therapies for multiple diseases where inflammation is a contributing factor, including Parkinson’s disease. In 2002, this promising avenue of research was given a boost when pioglitazone was shown to prevent the death of dopamine neurons in pre-clinical models of PD.

Marina Emborg In 2005, Marina Emborg, MD, PhD, director of the Preclinical Parkinson’s Research Program at the University of Wisconsin, received an MJFF Community Fast Track award to test the neuroprotective properties of orally administered pioglitazone in more relevant pre-clinical models of PD.

NH2 “We knew that pioglitazone might one day provide an innovative, simple and non-invasive strategy to prevent Parkinson’s progression,” says Dr. Emborg. “Furthermore, since pioglitazone is already known to be safe, it could HO be quickly translated into clinical trials in PD patients. MJFF funding was vital to our efforts to provide proof-of- principle for a new class of compounds to treat PD and other neurodegenerative disorders.” OH When Dr. Emborg’s preliminary data suggested that the active compounds of pioglitazone were neuroprotective, Chemical structure of pioglitazone MJFF provided supplemental funding to determine whether the doses used in pre-clinical models could be translated to humans. This work will provide critical data on optimal dosage to inform a clinical trial in PD patients slated to launch in 2010 with significant funding from NINDS, the National Institute of Neurodegenerative Disease and Stroke (NIH).

“Repurposing existing drugs for Parkinson’s could be a key approach to creating new and better treatment options for patients,” says Todd Sherer,”but it’s difficult for scientists to get funding for this kind of work. MJFF is committed to driving such efforts for the benefit of people living with the disease, and uniquely poised to do so.” Speeding Clinical Testing MJFF ANNUAL REPORT 2009 | 11

“I know a lot of foundations, and [MJFF is] amazingly well-organized, and they care. They really care what happens. I’ve never experienced this before. It’s a unique situation. That is why they are so successful.” Wolfgang Oertel

$29.4 million Lighting Up the Connection between Tobacco 2009 MJFF funding and Parkinson’s Disease to U.S.-based research teams Researchers and patients have long been intrigued Parkinson’s patients. (Study participants will by the link between tobacco and Parkinson’s be treated and observed for one year.) Principal $9.5 million disease. “There have been numerous compelling investigators Wolfgang H. Oertel, MD, and Marcus 2009 MJFF funding observations to suggest that tobacco exposure may M. Unger, MD, of Phillipps University Marburg, to international hold multiple benefits for PD patients,” says Carlie Germany, and Karl Kieburtz, MPH, of the University research teams Tanner, MD, one of the world’s leading experts on of Rochester, New York, will evaluate the disease- environmental factors in PD and a member of the modifying potential of transdermal nicotine using MJFF Scientific Advisory Board. “Epidemiological standard nicotine skin patches of the type used by studies consistently demonstrate that tobacco use millions of smokers as a quitting aid. lowers the risk of developing Parkinson’s disease, Speaking to the journal CenterWatch Monthly, and experiments in pre-clinical models have shown which reported on NIC-PD in its story “Michael that nicotine may protect dopaminergic cells from J. Fox Foundation Gives German Investigator- death. Several studies also suggest a symptomatic initiated Trial New Life,” Dr. Oertel said: “I know a effect, though small and somewhat variable. lot of foundations, and [MJFF is] amazingly well- And recent data shows that nicotine may reduce organized, and they care. They really care what levodopa-induced dyskinesias.” happens. They go to the advisory board meetings. Yet key questions about the relationship among [Usually,] the advisors meet without the scientists smoking, nicotine and Parkinson’s — including and then they are called in and either their head is whether the protection seemingly conferred by chopped off or they get the check. But, at Michael smoking tobacco products stems from the nicotine J. Fox, you meet for two days with the advisors and in those products, other components of tobacco, they go with you through all the topics. It’s amazing. or metabolic aspects related to smoking itself — I’ve never experienced this before. It’s a unique Wolfgang Oertel remain unanswered. situation. That is why they are so successful.” In 2009 The Michael J. Fox Foundation awarded “There’s no doubt that the epidemiological data on $1.1 million for NIC-PD, an international clinical smoking and PD is intriguing,” says Katie Hood, trial vetting the effects of nicotine skin patches on CEO. “Our priority is on taking action to validate Parkinson’s disease. It is the first long-term clinical this data clinically in order to potentially translate trial expressly designed to test whether nicotine it into a practical, patient-relevant therapy.” may in fact modify the progression of PD. The double-blind, placebo-controlled trial — the first-ever multisite, investigator-initiated collaboration between Parkinson’s research groups in Germany and the United States — will be conducted over three years in 150 newly diagnosed 12 | MJFF ANNUAL REPORT 2009 Scientific Progress Report

Targeting Glutamate to Treat Levodopa-induced Dyskinesias

Developing effective treatments to alleviate Programs. “This would lead to an enormous dyskinesias — the disruptive, involuntary improvement in patients’ quality of life.” movements that are a side effect of long-term The initial data on mGluR5 and dyskinesia came dopamine replacement therapy — is a high- from Angela Cenci-Nilsson, MD, PhD, of Lund priority research area for MJFF. In 2009 one University in Sweden. In 2005 Dr. Cenci-Nilsson promising approach involving glutamate — a received a Target Validation award to demonstrate neurotransmitter of increasing interest to PD that blocking the action of one particular receptor, researchers — moved forward to the early stages mGluR5, prevented levodopa-induced dyskinesias of clinical research. MJFF has been a champion in rodent models of PD. of an approach targeting a specific glutamate receptor, mGluR5,since 2005. The Foundation’s The Foundation quickly provided follow-on funding de-risking efforts have now chaperoned mGluR5 for Dr. Cenci-Nilsson to partner with Erwan Bezard, from basic discovery to clinical testing and PhD, of the University of Bordeaux in France. Their Angela Cenci-Nilsson attracted industry interest in the target. goal: take preliminary results to the next level in a more relevant model of PD. The pair worked closely “Finding new and safe treatments that can prevent with MJFF research staff to identify a compound dyskinesias would allow patients to continue on capable of reducing mGluR5 activity. Finding one levodopa, benefiting from its full symptomatic already in human clinical testing for another efficacy even in advanced stages of the disease,” disease, they adapted their studies to this compound Warning says Todd Sherer, PhD, vice president, Research to accelerate development toward the clinic. An important cautionary note: While MJFF is funding clinical trials on supplements and drugs already available for 80 purchase or prescription, people with Parkinson’s (other than 70 those who ultimately enroll in 60 these trials) should not begin taking these agents as part of 50 a Parkinson’s disease treatment 40 regimen without the explicit nvoluntary Movement recommendation of their doctor. I 30 Evidence to date has not yet definitively proved a benefit 20 bnormal A in PD, and these substances 10 carry potential health risks, which doctors will carefully 0 monitor in trial participants. -10 It is crucial that all care and 1 3 5 8 11 13 15 18 21 treatment decisions related to Parkinson’s disease and Session Days any other medical condition be made in consultation with Abnormal involuntary movement scores, a measure of dyskinesia severity, increase over time in parkinsonian models a physician or other qualified treated with levodopa (represented by red squares). This increase is blunted in models receiving treatment with an medical professional. mGluR5 antagonist as an add-on to levodopa (represented by blue triangles). The mGluR5 antagonist alone does not induce any abnormal involuntary movements (represented by yellow circles). Each data point represents the average value from eight to 10 models in each group. Speeding Clinical Testing MJFF ANNUAL REPORT 2009 | 13

“The Michael J. Fox Foundation’s staff are highly committed, truly capable people. They monitor your progress; they’re extremely aware of where Parkinson’s research is going and where it needs to go. They won’t fund a project just because it’s trendy, or because of a scientist’s famous name. Their goal is to promote quality research with high translational value, and they do everything to achieve that goal.” Angela Cenci-Nilsson

MJFF is now partnering with Danna Jennings, MD, What is the dose most likely to provide meaningful of The Institute for Neurodegenerative Disorders in clinical benefit? Our research aims to answer these New Haven, Connecticut, to verify the action of this questions.” compound and determine a safe and effective dose MJFF’s commitment has galvanized the field, $10.1 million for use in future clinical trials. Using PET scans prompting industry scientists to conduct clinical Amount of and a fluorescent imaging molecule that binds to testing of other compounds targeting mGluR5. research funded mGluR5, Dr. Jennings images PD patients’ brains “By driving pre-clinical development of promising by MJFF in 2009 before and after treatment. “An important step drug targets, MJFF is providing tangible incentives to address before investing in a large clinical trial is to make for industry to increase its involvement in Parkinson’s patients’ unmet sure that the drug is in fact getting to the brain and research,” concludes Dr. Sherer. “The development of needs including binding to the expected targets,” says Dr. Jennings. dyskinesia dyskinesia therapies based on mGluR5 activity is a “Is the drug reaching the brain at appropriate levels? perfect example of this strategy.”

U pdate Serotonin and Dyskinesia: MJFF Support Leads to Pilot Clinical Trial

Progress 2008 featured the efforts of Anders Björklund, PhD, and his colleague, Manolo Carta, PhD, of Lund University in Sweden to develop a new treatment for dyskinesia targeting the brain’s serotonin system, better known for its role in clinical depression. With Foundation funding, the researchers have now demonstrated that abnormal, dyskinesia-inducing dopamine release can be effectively blocked by drugs that act on two specific receptors, known as 5-HT1A and 5-HT1B, located on the serotonin neurons. They have also shown that this technique is particularly effective when the two receptors are activated simultaneously. Based on these results, Dr. Björklund’s team is now conducting an MJFF-funded pilot clinical trial in 24 Parkinson’s patients at Lund University Hospital and Karolinska Hospital Huddinge (both in Sweden). The trial is being carried out in collaboration with the U.S. biotech company PsychoGenics, using their proprietary drug Eltoprazine, which activates both 5-HT1A and 5-HT1B and has shown promising results in pre-clinical trials to date. Structure of the neurotransmitter serotonin 14 | MJFF ANNUAL REPORT 2009 Scientific Progress Report

Mobilizing New Technologies and Tools in PD Therapeutic Development

To advance therapeutic targets toward the clinic requires highly specialized tools and technologies, whose development in itself requires significant financial and intellectual investment. But there is no financial incentive for any single stakeholder to allocate major funding to this critical need. MJFF, with its singular focus on Scientific P r o g r e s s patient-relevant outcomes, is uniquely positioned to marshal the resources and R e p o r t partners that can propel development of tools and technologies with potential to move the entire field forward.

Using Virtual Reality to Address Freezing of Gait

An MJFF-funded team in Sydney, Australia, is using functional magnetic resonance imaging (fMRI) in a virtual environment to visualize patients’ brains while safely triggering freezing of gait episodes. The project is part of a $2-million MJFF commitment to therapeutic development for postural instability and gait disturbances in Parkinson’s disease, made possible with lead funding from The Edmond J. Safra Foundation. While lying in the MRI scanner, patients will use foot pedals to ‘walk’ through a realistic three-dimensional environment they see on a small screen. The virtual environment task will probe cognitive processes that often provoke freezing episodes (such as sliding doors) or alleviate them (such as striped floors). “We hypothesize that rather than simply reflecting a process related to gait, freezing episodes are in fact related to a breakdown in the circuitry that coordinates different functions such as movement and thinking,” says principal investigator Simon Lewis, MD. “We want to identify the abnormal pattern of brain activation — hopefully increasing understanding of freezing and opening new directions for targeting therapy.” Simon Lewis

“Throughout all my experiences with MJFF I’ve been impressed with the rigor and accountability of the Foundation’s process, and with the creative and competent way that the staff goes about its mission of finding better treatments and a cure for Parkinson’s disease. I’m willing to dedicate as much time and effort to the Foundation as I do because I truly believe this organization is going to make a difference.” Gene Johnson, PhD, Chief Scientific Advisor, MJFF

MObilizing New Technologies MJFF ANNUAL REPORT 2009 | 15

Maximizing Learning from At-risk Populations: MJFF Drives LRRK2 Cohort Studies in New York, Tel Aviv and Tunisia

On page 7 you read about the LRRK2 biology consortium, part of Medical Center and the Institute for Neurodegenerative Disorders is MJFF’s strategy to increase understanding of the LRRK2 gene that is tracking Ashkenazi Jews in New York and in Tel Aviv, Israel. believed to be the single most common contributor to genetic cases “Not all people with LRRK2 mutations get PD, and for those who do of Parkinson’s disease. The Foundation is simultaneously working to develop the disease, there is great variability in symptoms,” says define the clinical impact of LRRK2 on PD — that is, how LRRK2 may Susan Bressman, MD, of Beth Israel Medical Center, coordinating cause or prevent specific symptoms, impact rate of progression, or principal investigator for the New York/Tel Aviv cohort. “By studying otherwise affect disease severity and trajectory. large numbers of people with the same mutation, we can start to The Foundation is funding two research teams to study PD in cohorts of understand its implications for risk and disease course in individuals.” Ashkenazi Jews and North African Arab-Berbers, two populations with a To ensure that all data collected can be analyzed, shared and compared significantly elevated incidence of the PD-implicated LRRK2 mutation as efficiently and meaningfully as possible, MJFF worked with the known as G2019S. What they learn will not only provide answers about investigators to set up collection methods standardized across both what it means to have a LRRK2 mutation, but also open new avenues cohorts. This will improve the ability of the researchers to compare of therapeutic development for people with the far more results and link clinical features to underlying biological common sporadic form of the disease. and genetic processes. A team of investigators from Mayo Clinic, “By studying these uniquely affected populations, Jacksonville, and the Institute of Neurology in Tunis our goal is to make drug development efforts centered is following an Arab-Berber cohort in Tunisia. A on LRRK2 more efficient and ultimately speed patient- second group comprising investigators at Beth Israel relevant outcomes from this work,” says Katie Hood, CEO. Medical Center, Columbia University, Tel Aviv Sourasky

A Critical Step toward Controlling Dyskinesia

The drug levodopa is the gold-standard treatment for relieving the In 2009, as part of its ongoing efforts to drive new dyskinesia stiffness, tremors and rigidity of PD. But patients are forced to weigh treatments, The Michael J. Fox Foundation announced a $1-million symptomatic relief against the knowledge that, at some point, levodopa clinical study to validate effective dyskinesia scales. The multi-site will very likely cause dyskinesia. Patients wait as long as possible to study, led by Christopher Goetz, MD, at Rush University Medical Center begin levodopa; even after starting, many limit dosage to reduce the in Chicago, will aim to conclusively identify the scales that most risk of dyskinesia. If dyskinesia develops, patients often reduce their accurately measure dyskinesia. levodopa dose and settle for a lesser benefit from the best medical The experimental design involves amantadine, a current, albeit therapy available for their disease. inadequate, drug frequently used off-label to treat dyskinesia. Dyskinesia is a moving target in every sense of the phrase. It takes Patients will be treated with amantadine or placebo, and then have different forms and varies widely from day to day and even hour to their dyskinesia rated over the course of several weeks using hour. Partly for this reason, the development of accurate clinical numerous dyskinesia measurement scales. (The researchers will scales to detect type, severity, duration, and impact on the patient has examine the response to placebo as well, in order to favor scales that been elusive. While several scales exist, their effectiveness has never maximally separate placebo-associated changes from amantadine- been rigorously compared. Without scales the scientific community associated changes.) The results will establish a path for clinical has confidence in, there is no framework for clinical testing of testing of future promising novel dyskinesia treatments, increasing possible new treatments. This in turn creates a hurdle to biotech and the likelihood of industry investment in future clinical trials. pharmaceutical companies investing in the development of potential new dyskinesia therapies. 16 | MJFF ANNUAL REPORT 2009 Scientific Progress Report

Model Techniques for Speeding PD Drug Development

Pre-clinical models are vital tools for drug more closely mimic many behavioral aspects development. Researchers require good models to of human Parkinson’s disease, offer a greater increase understanding of cellular, molecular and amount and wider range of tissue for testing and behavioral aspects of disease, as well as to screen allow scientists to conduct certain tests that are potential new therapies before they move forward impossible in mice or non-mammalian models.” to testing in humans. Parkinson’s therapeutic Sigma-Aldrich used a novel technology called Zinc development is held back by the lack of any pre- Finger Nuclease (ZFN). It causes targeted breaks clinical model that accurately recapitulates both in double-stranded DNA that can snip out specific the underlying processes, and the symptoms, of genes of interest. ZFN was developed by Sangamo the human condition. Even when good models are BioSciences and licensed to Sigma-Aldrich in 2007. developed, better distribution channels are required Its application in rats would later be named one of to quickly get them into researchers’ hands. the top 10 scientific innovations of 2009 by The Scientist.

Zinc Finger Nuclease By August MJFF had awarded a Sigma-Aldrich team (ZFN) must be led by Edward Weinstein, PhD, a one-year grant delivered as a pair b) FokI to develop five Parkinson’s knockout models, each to be functional. lacking one gene known to play a role in PD: alpha- When all ZFN components are 5’-ATCCTGTCCC TAgtggccCCACTG TGGGGT- 3' synuclein, LRRK2, DJ-1, Parkin and PINK1. The properly assembled, 3'- TAGGAC AGGGAT cacc ggGGTGACACCCCA - 5' creation of knockout rat models of PD will provide a highly specific pair FokI new opportunities for understanding the functions of ‘genomic scissors’ is created. of different PD-implicated genes. The researchers a) expect to report back to MJFF on the creation and characterization of their models by mid-2010.

A pre-clinical model shows the effects of a human LRRK2 mutation The development and distribution of improved In 2009, with funding from MJFF under the models is a major priority for MJFF, and in 2009 the Development of Progressive Pre-clinical Models of Foundation’s efforts bore significant fruit. PD initiative, CJ Li, PhD, of Weill Cornell Medical College published the first reported mouse model Knocking out PD for the study of LRRK2 gene mutations. (Read A laboratory technique known as gene knockout lets more about LRRK2 on page 4). Unlike the knockout scientists working in pre-clinical models remove rats, Dr. Li’s mouse models express the human a specific gene of interest, effectively turning it LRRK2 gene, allowing scientists for the first off (“knocking it out”), allowing them to study time to evaluate the progressive effects of these genes’ effects on cellular disease processes. Gene gene mutations — a critical step in the process knockout has been used for decades in laboratory of converting genetic discoveries into patient- mice, but never successfully in rats until July 2009, relevant therapies and a vital need for biotech and when biotech Sigma-Aldrich published proof-of- pharmaceutical companies working to develop new principle for the first knockout rats. treatments for Parkinson’s. “Rats offer numerous advantages as models for “Dr. Li’s models represent a much-needed pre- Parkinson’s drug development,” says Todd Sherer, clinical tool to screen and validate potential PhD, vice president, Research Programs. “They new therapies for Parkinson’s disease,” says MObilizing New Technologies MJFF ANNUAL REPORT 2009 | 17

“The Michael J. Fox Foundation for Parkinson’s Research didn’t waste any time putting recently published knockout rat technology to work.” Science-Business eXchange (cover story), October 22, 2009

MJFF Scientific Advisory Board member Kalpana models, in 2009 MJFF partnered with The Jackson Merchant, PhD, of Eli Lilly and Co. “They also can Laboratory (JAX) in Bar Harbor, Maine, to strengthen be used to study the underlying mechanisms of JAX’s existing Parkinson’s Disease Mouse Model LRRK2 mutations and how they contribute to PD.” Repository. MJFF has quickly provided supplemental funding The repository will house and distribute valuable to Dr. Li and collaborator J. Timothy Greenamyre, MJFF-funded mouse models for use by the entire PD 5 MD, PhD, of the University of Pittsburgh to research community, removing a significant barrier MJFF partner Sigma- further characterize neurobehavioral deficits, to access. The mouse models created by Dr. Li and Aldrich’s position in The neurochemical irregularities, dopamine cell loss, his colleagues, as well as other pre-clinical models Scientist’s Top 10 scientific neuropathology, and molecular features in models developed with funding from MJFF, are already at innovations of 2009 for of different ages. JAX and ready for distribution. its novel knockout-gene technology “We anticipate that these models of PD will “Working with JAX is one example of how MJFF is recapitulate various components of the human doing whatever it takes to speed drug development disease,” says Dr. Li. “This increases the potential by getting the best research tools into as many that meaningful comparisons can be made between scientists’ hands as possible,” says Sohini what we find in the models and what is seen in PD Chowdhury, associate director, team leader, patients.” Research Programs. “We can’t stand by and watch access issues slow down research progress.” Practical distribution channels for

widespread access to the best tools To reduce the costs and improve the speed and efficiency of producing and distributing research

CJ Li (right) 18 | MJFF ANNUAL REPORT 2009 Scientific Progress Report

Our Global Reach: Select List of Organizations with Active MJFF Awards in 2009

With up to 250 active awards in our portfolio at any given time, The Michael J. Fox Foundation is continuously engaging with Parkinson’s disease researchers and thought leaders across the globe. Below are the organizations, companies and institutes that initiated new MJFF-funded PD research projects in 2009.

United States Mayo Clinic University of Florida Germany Acadia Pharmaceuticals Medtronic Neuromodulation University of Illinois at Chicago InterMed Discovery GmbH Adolor Corporation Montana State University University of Iowa Max Planck Institute for Alzheimer Research Forum Mount Sinai School of Medicine University of Pennsylvania Biophysical Chemistry Amylin Pharmaceuticals, Inc. National Institute on Aging (NIA)/NIH University of Pittsburgh NextPharma ArmaGen Technologies, Inc. Northern California Institute for University of Rochester University Hospital Goettingen Beth Israel Deaconess Medical Center Research & Education University of South Florida Philipps University Marburg Northwestern University Biodesy, LLC University of Southern California Greece Oregon Health & Science University Brandeis University University of Texas Foundation for Biomedical Brigham & Women’s Hospital Parexel University of Texas Southwestern Research of the Academy of Athens Brown University Pfizer Global Research and Medical Center at Dallas Development Ireland Caliper Life Sciences (Xenogen) University of Washington Purdue University Opsona Therapeutics LTD Carmot Therapeutics, Inc. Virginia College of Osteopathic Retrotope, Inc. Medicine Case Western Reserve University Israel Rockefeller University Wayne State University Ceregene, Inc. Hebrew University-Hadassah Rush University Weill Medical College Medical School Chaperone Therapeutics, Inc. Saint Jude Children’s Tel Aviv Sourasky Medical Center Codman and Shurtleff, Inc. Research Hospital Australia Colorado State University Satoris, Inc. University of Sydney Italy Columbia University Sigma-Aldrich University of Melbourne University of Brescia Coriell Institute for Medical Research Sign Path Pharma. Inc. Austria University of Padova Covance SRI International University of Innsbruck Spain Creative Commons Stanford University Belgium Universidad Autonoma de Madrid Duke University Sun Health Research Institute University of Liege Emory University Targacept, Inc. Sweden Katholieke Universiteit Leuven Envivo Pharmaceuticals The Burnham Institute for Medical Lund University Research reMYND NV 761 Epitomics Switzerland FoldRx Pharmaceuticals, Inc. The Institute for Neurodegenerative Canada Number of grant Disorders Swiss Federal Institute of Foundation for the National Institutes University of Alberta Technology Lausanne applications of Health The Jackson Laboratory University of Ottawa Tunisia reviewed by Harvard University The Parkinson’s Institute NeurAxon, Inc. National Institute of Neurologyy MJFF in 2009 Henry Ford Health System The Salk Institute for Biological Studies Toronto Western Hospital In Silico Biosciences United Kingdom Thomas Jefferson University Neurodyn Inc. Indiana University PRN University of Alabama at Birmingham Intra-Cellular Therapies, Inc. Denmark University of Dundee University of California, Los Angeles Invitrogen Corporation University of Aarhus University of Cambridge University of California, San Francisco Isis Pharmaceuticals, Inc. GlaxoSmithKline University of Chicago France Life Technologies Imperial College London University of Cincinnati University of Bordeaux Louisiana State University Health University of Nantes Institute of Neurology Sciences Center-Shreveport University of Colorado at Denver & Health Sciences Center INSERM University of Newcastle upon Tyne Massachusetts General Hospital University of Colorado Denver Toulouse University Hospital Scientific Progress Report MJFF ANNUAL REPORT 2009 | 19

Our Power to Convene: Select List of 2009 MJFF Workshops and Summit Meetings

In 2009, MJFF brought together more than 500 top researchers from academic and industry labs all over the world for approximately 40 conferences, summit meetings and workshops. These sessions catalyzed concrete action steps — new grant programs, funding for critical tools and resources, novel collaborations “MJFF’s PD Therapeutics Conference is an essential and other tactical interventions to move the best ideas forward faster. meeting for PD drug ADDF Drug Discovery for Neurodegeneration, Third Annual PD Therapeutics Conference, development because of its February 2–3 September 30 focus on what really matters: (Sponsored by the Alzheimer’s Drug Development Nearly 200 academic and industry researchers and presenting the highest- Foundation) business development professionals attended the impact research ideas and Todd Sherer, PhD, vice president Research only major scientific symposium exclusively focused compelling data. The goal is Programs, chaired a session on drug discovery on speeding PD therapeutic development. to streamline the process of and development for neurodegenerative diseases. Participants brainstormed potential solutions to Industry Strategy Session, aligning suitable partners October 8 and forging effective new issues including selection of research models, target validation and pre-clinical development. Global leaders of biotech and pharmaceutical collaborations.” firms provided crucial feedback on MJFF’s efforts Placebo Response Workshop, to engage industry to date. Participants also Franz Hefti, PhD, Chief Scientific Officer, March 30 suggested next steps on de-risking Parkinson’s Avid Radiopharmaceuticals; (Co-funded by The Davis Phinney Foundation) drug targets and explored additional ways that the Chair, PD Therapeutics Leading experts prioritized strategies for gaining Foundation could partner with industry to speed the Conference 2010 a greater understanding of placebo effects in development of transformative treatments and a Parkinson’s to improve the design and testing of cure for PD. future therapeutics. The placebo effect — in which patients who receive an inert substance nonetheless Partnering for Cures, December 1–3 experience some or all benefits of active treatment — has increasingly complicated the interpretation (Sponsored by FasterCures) of outcomes from PD clinical trials, creating a Katie Hood, CEO, Debi Brooks, co-founder, and significant hurdle to the development of new senior MJFF staff members participated in this treatments. first-of-its-kind meeting that brought together 535 philanthropies, medical research foundations, Number of Next Steps on Dyskinesia, and the biopharmaceutical industry in an effort researchers June 3 to forge strategic collaborations key to the timely convened by MJFF World-leading experts on dyskinesia, including development of new medical treatments. for 40 strategic members of the Foundation’s Dyskinesia Working meetings in 2009 Group, assessed the status of various therapeutic LRRK2 Summit, December 9 approaches to alleviating this debilitating complication of long-term dopamine replacement Global experts in PD genetics assessed the state therapy, and prioritized strategic next steps for MJFF of the field in LRRK2 biology and therapeutic and the field. development, evaluated MJFF and field-wide activities, and recommended actions for MJFF and the field to accelerate understanding of the role of LRRK2 and its translation into meaningful therapies for people with Parkinson’s disease. 20 | MJFF ANNUAL REPORT 2009 year in photos

1

2

3 4 5 6

7 8 9

1. Julianne Moore and 3. Board member David Einhorn 7. Michael J. Fox and Stevie Wonder 2009 in Photos Bart Freundlich. and his wife, Cheryl. at “A Sunny Thing Happened 2. Gregg Allman, Denis Leary, 4. Amar Kuchinad, the top Team on the Way to Cure Parkinson’s Sam Fox, Elvis Costello, Fox fundraiser of 2009, after the Disease.” Roger Daltry, Michael J. Fox, NYC Half Marathon. 8. Allison Maguire and Brian John Popper and Steven Tyler 5. Board member Ryan Reynolds. Grant (formerly of the Portland backstage at “A Funny Thing Trailblazers). 6. Twins Drew and Kyle Shackleton Happened on the Way to Cure 9. Rachael Ray and John Cusimano. Parkinson’s Disease.” run the Chicago Marathon for Team Fox, qualifying for the Olympic trials in the process. year in photos MJFF ANNUAL REPORT 2009 | 21

10 11

13 14

12

15 16

10. MJFF Board Chair George 12. MJFF Co-Founder Debi Brooks 15. Michael J. Fox, Martin Prescott and his daughter, and Patient Council member and Helen Scorsese Cheri. Eugenia Brin. and Ronald O. Perelman. 11. Board member Al Glickman 13. David and Paige Glickman, 16. Scott Fahey, Board member with his wife, Judy, and hosts of “Sunny Thing” 2009, Doug Ostrover, MJFF CEO Michael J. Fox. greet guests from the stage. Katie Hood, Scott Williams 14. Tracy Pollan and Michael J. Fox. and Board member Curtis Schenker. 22 | MJFF ANNUAL REPORT 2009 Donor Listing

2009 Donor Listing

In 2009, with the help of more than 56,000 individuals, corporations and foundations, The Michael J. Fox Foundation funded over $39 million in Parkinson’s research. We are deeply grateful for our donors’ ongoing commitment to our mission to discover breakthrough treatments for Parkinson’s disease. This report lists those who honored us with significant contributions last year. Also listed are the many friends and family members to whom they paid tribute with their donations. It is in their name and spirit that we work with continued urgency toward a cure.

$25,000,000 or more $1,000,000 or more The Brin Wojcicki Foundation Margaret C. Glosser Trust Judy and Al Glickman/ $10,000,000 or more Albert Glickman Family Foundation Chris Sullivan* Anne and Burt Kaplan* Shackleton Family* $2,000,000 or more EMD Serono* $500,000 or more Kinetics Foundation* Benaroya Foundation Judith and George Prescott and Family* Donny Deutsch* The Edmond J. Safra Foundation* Elan Pharmaceuticals, Inc.* The Dotha S. Welbourn Great Investors’ Best Ideas Charities Trust Foundation/Michele and Shad Rowe

*recognizes multi-year commitment Donor Listing MJFF AnnuAL REPORT 2009 | 23

$250,000 or more The Greater Kansas City Community Merck Stephen and Carolyn Chase Foundation & Affiliated Trust Estate of Sam M. Anderson Meredith Whitney Advisory Group City Arts & Lectures, Inc. Carolyne and Edwin Levy Cheryl and David Einhorn Mirken Foundation Close To A Cure Jennifer and Marc Lipschultz Lisa Piazza and David Golub* Catherine and John T. Morse Nancy and Samuel D. Colella Joella and John Lykouretzos Greenlight Capital, Inc. Park Foundation The William E. Connor The Mann Family Foundation Foundation, Inc. Shannon and Mark L. Hart III Pfizer, Inc. Zella M. McClure Consolidated Anti-Aging Estate of John Christopher Kimmey Julie Turaj and Robert Pohly Foundation The Miller Family Foundation Lazard Capital Markets Rawley Foundation Cossette Communication, Inc. Edna May Minnick Estate Jean Patton 2005 Revocable Trust Joshua Rosman The Anthony M. Cotoia Newman’s Own Foundation, Inc. Carolyn and Curtis Schenker Carolyn and Marc Rowan Foundation, LLC. Oak Creek Foundation Karen Pritzker and Michael Vlock Rick Rucker — Lawrence County Basil J. Coughlan II Pershing Square Capital Managment Parkinson’s Association Rachael Ray and $100,000 or more Prince Charitable Trusts Elizabeth and Scott Schefrin John Cusimano Anonymous (2) Caroleen Feeney and Richie Lisa Rotmil and Alex Schmelzer Norah and John Daly Estate of Helen Bennett Rothenberg Hilary Bates and Jerome Simon Eleanor and Peter Daniels Shanna and Jon Brooks Solvay Pharmaceuticals The Melvin and Bren Simon Josefina Diez Virginia Brooks* Katherine Farley and Jerry I. Speyer Charitable Foundation Mr. and Mrs. Edward J. Dobbs BTIG, LLC Winthrop H. Smith Family Foundation $25,000 or more Cheryl and Blair Effron The James E. Cayne and Patricia D. Anne-Cecilie Engell Speyer Anonymous Craig Effron and Company Cayne Charitable Trust and Rob Speyer The Jeffrey A. Altman Foundation Thomas and Jeanne Elmezzi Joyce and Barry Cohen Suwyn Family Foundation* Private Foundation Bloomberg J. & F. Coody Inter Vivos Trust Mildred E. Swanson Foundation The Emerson Hermetic Motor Division Julie Bowen and Scott Phillips Cantor Fitzgerald Teva Pharmaceutical Industries Ltd. Lois and Richard England Family Estate of Ruth Carter Tracy Pollan and Michael J. Fox Maida and Ralph W. Tyron Foundation Ellen Hooker and Joseph Cassano The Sol and Lillian Goldman Family Ullmann Family Foundation, Inc. The Ettleman Family Fund Morgan Management — Robert Karen Finerman and Viacom International, Inc. Mary Kay Fitzsimmons Morgan, Robert Moser, Chase Chavin Lawrence Golub and their families Amy and Fred Weiss Dr. Marsha Heinke and John and Amy Griffin Foundation Dr. Lawrence Forthofer Sonya and Dev Chodry Kimberly Williams-Paisley and The Leona M. and Harry B. Helmsley Brad Paisley Julianne Moore and Stuart Clifton Charitable Trust Bart Freundlich Steven and Alexandra Cohen $10,000 or more Holly Andersen, MD, and Friedman Family Foundation Foundation Douglas Hirsch* Anonymous (8) Orrie M. Friedman Charitable Fund Camille and Michael Costa Rachel and Amar Kuchinad Lisette Ackerberg Christen C. & Ben H. Garrett DEARS Foundation, Inc. Dorothy L. Lesher Estate Allen & Company Family Foundation Deutsche Bank Securities, Inc. Allison and Casey Maguire Alpha Search Advisory Partners , LLC Jayne Godfrey Dillard’s, Inc. Julie and Doug Ostrover Ammon Foundation Stephanie and Robert Goldstein Jane and Rudolph DiNunzio Parkinson’s Unity Walk Avenue Capital Group Meg and Bennett Goodman Norma Doering* Ronald O. Perelman Barclays Capital Brian Grant Eva Andersson-Dubin, MD, and Robert Pritzker Sylvia M. Becherer The Grateful Foundation, Inc. Glenn Dubin The Pumpkin Foundation/Joe Amanda Peet and Ellyn and Michael Greenspan Valerie Feigen and Steven Eisman and Carol Reich David Benioff Jennifer and Bud Gruenberg Richard H. Fitzgerald Mrs. Edmond J. Safra Melissa E. Benzuly Debbie and David Horn Lee Fixel Carl and Ruth Shapiro Family Andrea Billhardt The Howard Family Charitable Fund Foundation Jay Goldman Eric Blecker Ann and Skip Irving Susan and Kim Henry Rita and Irwin Blitt $50,000 or more ITSource Technology Buddy and Edna Herring Christina Bloom Anonymous (3) J.J.C.T.M. Foundation Armin & Esther Hirsch Foundation Margo and Mitchell Blutt Bachmann-Strauss Dystonia and The Rona Jaffe Foundation Parkinson Foundation, Inc. Marjorie and Robert Hirschhorn Donya and Scott Bommer/ SAB Patricia Jehle Sara and Kate Bloom Fund Ionic Capital Management Capital Management Jet Capital Management Boehringer Ingelheim Sonia and Paul T. Jones W. L. Lyons Brown Foundation The Robert Wood Johnson Foundation Pharmaceuticals, Inc. The Kellar Family Foundation William O. Burnett Foundation Eleanor Francis Nelson Jordan Claire and Jason Capello The Lauder Foundation Patrice M. Campbell JP Morgan Chase Foundation Barbara and Julian Cherubini Douglas Liebhafsky and Wendy The Carmen Foundation Ellen Francesca Judge Estate of Beryll Deming Gimbel Charitable Fund Stephanie and Wayne Caron Drs. Julie and Scott Kalniz French American Charitable Trust Margaret Munzer Loeb and Donna and Jake Carpenter Daniel Loeb Susan and Nicholas Carter *recognizes multi-year commitment continued on page 25 24 | MJFF ANNUAL REPORT 2009 Donor Listing

MJFF Becomes a Registered Canadian Charity

In 2009, The Michael J. Fox Foundation became a registered, tax-exempt charity in Canada, making all donations to MJFF from Canadian residents tax-deductible to the full extent of the law. Said MJFF founder and Canada native Michael J. Fox, “We have always been fortunate to be on the receiving end of a steady outpouring of Canadian support for our efforts to speed a cure for Parkinson’s. Canadian researchers have also been actively involved in our scientific agenda since our earliest days. It’s tremendously meaningful to me that our Foundation is now an officially registered charity in my home country.” The Foundation is grateful to these Canadian friends for their generosity in 2009.

Doris Adams J. Moffat Dunlap Mount Allison University Rivers Reid Ranscombe Aerial Communications Group, Inc. Emblem Steve Klassen RBC Dominion Securities, Inc. Apotex Foundation EnerSpectrum Group KPMG LLP RBC Foundation James William Ashcroft Peter Farmer Krembil Foundation Heather M. Regent Steve Atkinson David Feldman Roger D. Lace Andy Renton Andy C. Barrie Franmed Consultants (1993), Inc. Esther Lamoureux Natalie Rosen Michele Bebis Fraser Milner Casgrain LLP Nancy Lang Sage Investments Limited The Bitove Foundation Paul A. Fredricks Christine Leslie The Sauder School of Business Kathy Blackmore Dr. Bruce V. Freeman Paul F. Little Rob Scheifley Francois Bourret Stanley Fujarczuk Andre Longpre Ianna Selkirk Michael Bregman Galin Foundation Matthew MacGregor Hemant Sharma Canaccord Capital Corporation Sheldon Garfinkle Janet Mackinnon Erin Sheard Claire and Jason Capello GiveMeaning Foundation Rosa MacLeod Ferne Sherkin-Langer Nina Castle Richard Goldberg Malcolm Marcus Dr. Shaun Singer Yves Chabot Geoffrey Gouinlock Joyce Mason Gale Single James Chmiel Chris Grannan Soania and Arun Mathur Mitra Singh Church Street The Place for Steak Griffiths McBurney Canada Corp Leslie McBeth Dr. Paul Slavchenko Virginia Cirocco Dr. Milan Gupta Cheryl and Rob McEwen Michael Spanier Catherine E. Clark Andrew S. Haibeck Mike McPartland Maureen Squibb Judith L. Cohen Nancy M. Holland Joseph M. Meaden St. Joseph Communications Roberta R. Cooper John C. Hamilton Medtronic of Canada Ltd. Simon Stanlake Sherry S. Cooper The Poul Hansen Family Merz Pharma Canada Ltd. Michael L. Stein Bruce Cornell Tennys J. Hanson Henry S. Mews Ronnie Strasser Cossette Communication, Inc. William H. Hatanaka Minuk Construction & Carol Grant Sullivan Engineering Company Creative Colour & Linda Elizabeth Hazen Charles W. Tellett Communications, Inc. Endowment Fund William Moll Telus Corporation Dahlman Rose & Company, LLC Adam Hegge Annick Mullen Levino Tittaferrante Eleanor and Peter Daniels Paul Higgins John Mullen Toronto General & Western Jennifer D’Aoust Jane Hill National Bank Financial Group Hospital Foundation Jamin Davies Susan E. Hillary Kristy and Eric Nuttall Bruce Towler Lisa de Lusignan Bethany Hoffman Thomas J. Obradovich Caird Urquhart Marc C. Deslongchamps Beth S. Horowitz Osler, Hoskin & Harcourt LLP Deb Voorheis Distort, Inc. Minnie Horowitz Dr. Shekhar Pandey G. Wesley Voorheis Heli Donaldson HSBC Bank Canada Parkinson Society Canada Deborah Walter Karin and Christopher Downie I.P. Rosati Holdings Limited Paul Pathak Michael A. Wekerle Downtown Fine Cars, Inc. JTB International (Canada) Ltd. Joanna Pedersen Andrea Witzel Dr. Thomas Morton Medicine Justine Blainey Wellness Centre Rebecca Philps Robert D. Wortzman Professional Corporation Jonathan Kaida Louise Poelzer York University Foundation — Rupert J. Duchesne Kalex Equipment Services Dr. Mani Raman Foundation de I’Université York Dr. Anil Kapoor Dr. Sunil Kapoor Donor Listing MJFF AnnuAL REPORT 2009 | 25

$10,000 or more (continued from page 23)

The Kay Family Fund Sheila and Tripp Smith The Boston Foundation Jeffrey Hamer The Keyser Family Judith Smolin Mark J. Boujoukos Jonathan M. Harris Family Foundation Patricia Stonesifer and Henry Spector Eugenia Brin Kathy Harris Michael Kinsley Corey Hajim and Jim Sperber Ms. Leila Kamal and Mr. Andrew The Claudia Hearn and Edward Stern The George Kress Foundation, Inc. Stupell Foundation, Inc. Brockway Foundation Jenny Hewlett and Michelle and Howard Swarzman Brokerage Unlimited Incorporated Wandy and William Hoh Adam J. Kutas Leah and Steven Swarzman Nicole and Brad Brooks James Holmes Martha Lam Jack Taylor Debi and Jeff Brooks Judith and Michael Hooffstetter Amalia and Peter H. Lucas Levino Tittaferrante Brown Charitable Foundation Benjamin and Jessica Hoyer Tami and Fredric Mack Sophia Tomich Living Trust Bruno-Shayegani Family Foundation Jesse Itzler Janet and Tim Maher Karin and Kenneth Travis Paul Chan Lisa and Lamar Johnson Soania and Arun Mathur U. S. Bank, The Private Client Reserve John Chuck Mr. and Mrs. David O. Jones Maverick Capital Foundation United Talent Agency Bruce Cohen Candace Leeds and Ed Katz Howard McClure Leslie and Bill Vollbracht Gloria Cohen Joy and Eric Kaye Trish McEvoy Remer and Donald Waguespack Stephanie and Chase Coleman Mary and Richard Ketchum Dennis M. McIntosh I. Waldbaum Family Foundation Toby Cooper Mary Kilfoy Barb and Terry Meguid Reid and Stacey Walker Courageous Steps for Parkinson’s Kathryn and Richard Kimball Kalpana Merchant Estate of Margareth M. Wall CSRA PD Support Group Walkathon Paul Klinger Norman A. Merollis The Walsh Family Dawn and Edward D’Alelio Marjorie and Russell Knauer Patricia and Wallace Mersereau Dr. Brent and Terry Weinberger Larry and Anne Davis Mrs. William T. Knight, III Bette Midler Katie B. Whorton Gavin De Becker John & Evelyn Kossak Foundation, Inc. Sandra Milken Bill and Sara Wilkins Jill and Jeffrey Degen Nyssa and Bill Kourakos Marilyn Muir Joan B. Wilton James G. DelMauro Kramer Levin Naftalis & Frankel LLP Nationwide Foundation Joe and Carol Wishcamper Fund Mark Dickstein Guymon Casady and Eric Kranzler Nancy and Bruce Newberg Daniel Wolf Ms. Valerie A. DiFebo and Mr. James Christina and Barry Kringstein Kim and Richard Nicely D. Byrne Barbara and Stanley Zax Esther Lamoureux The Donegan-Burns Foundation Jennifer and Sean O’Neal Linda and Alan Landis $5,000 or more Mary E. Dooner Foundation, Inc. Parkinson Association of Lark Hall Films Northern California Anonymous (3) Hillel Drazin Blanche & Irving Laurie Foundation PCG Corp. 1 Nina Abrams Fund Donald D. Drobny Dr. and Mrs. Lawrence E. Lee The Geraldine and Eugene Acadia Pharmaceuticals Catherine Boshaw and Pergament Education Fund Lee Family Fund Sigma Advanced Genetic Doug Edlund The Leibowitz & Greenway Family The Pioneer Fund Engineering (SAGE) Labs Drs. Jane and David Eger Charitable Foundation Estate of Marjorie D. Pippie Kenneth Aidekman Family Foundation Amelia Feinburg Gloria Levine & Harvey Levine Corky and Stephen Pollan AK Steel Foundation Firman Fund Charitable Foundation Jill and Mark Rachesky Nonie and Larry Akman Fund of Bill Fischer Kathy and Michael J. Lewis the Community Foundation for the Bobbi and George Rainwater Fowey Light Fund, Inc. Light Of Day Foundation National Capital Region Debbie and Rob Rodin Fox Family Foundation Holly and Jonathan Lipton Paul B. Albritton Allen Rosenberg Pamela and George J. Fox Deborah and Jim Long ALL TRI, Inc. Beatrice Rosenthal Lynn and Joel Frank M & T Trust Jack and Sylvia Altman Foundation Georgina and Alan Rothenberg Joyce A. Friedman Robert Macklin Amicus Therapeutics, Inc. Pablo Salame Ron and Linda Galowich Ellyn and Michael Maguire Marlene and Daniel Arbess Julie and Gary Salomon Ellen Gaslow Roxanne Majka Karen and Gregory Arrese Estate of Eileen R. Salter Kathryn and Oliver Gill Make It Possible Foundation, Inc. Babior Foundation Pam and Jon Scarborough GiveMeaning Foundation Marla Meg Gordon, Kornstein Veisz Lino J. Bailo Trust Francesco Scattone Paige and David Glickman Wexler & Pollard, LLP Lois Barnard Schaner & Lubitz, PLLC Deborah and Brian Gottlieb Mary and Robert Mandell Mario Batali The Edward I. Seagraves Fund The Tom and Bonnie Grace Family Gary Marks Elaine J. Beresh William and Jacqueline Shaw Family Foundation Kathleen Kennedy and Frank Marshall Robin Berman, MD, and Foundation Wally and Charlie Graham John and Maude Matouk Charitable Ed Berman Patti and Martin Shenkman Mr. and Mrs. Alan C. Greenberg Foundation and Family Biotechnology Industry Organization Jeff and Mei Sze Greene Foundation Mayer Family Foundation Jill and Bill Shepherd Debra and Leon Black Laura and William Gruy Cindy and Mike McConnell Elsa and Stanley Sidel Dan & Merrie Boone Foundation Eugene Gurkoff Helen M. McGinn Jean S. Smith Revocable Trust continued on page 26 26 | MJFF ANNUAL REPORT 2009 Donor Listing

$5,000 or more (continued from page 25)

Stefanie Meisel and Scott Macklin Signature Bank Lawrence Butler Adele and Mark Hart, Jr. Jodi and Kenneth Meister Mr. and Mrs. Donald Simon Patricia and Alfred Byrnes Nancy Hausman Merkle Response Management Group Mary and Robert Slaughter California Jurisdictional Convention June M. Haverly Leo Miller Family Foundation Sony Corporation of America Linda and Alexander L. Cappello Sharra L. Haynes Estate of May Moore Tina and Mark Stacy Jock Casasus Health Advances, LLC Carolin Moran Carol and Jim Storm Ruth Jones Casey Foundation Sheila and Jonathan Herr Elizabeth Moran Jennifer and John Streit Ceregene, Inc. Daniel Herz Donald Mullen Pamela and Jeffrey Swartz Yves Chabot Tom Heymann Beth and James Kevin Murray Tamkin Foundation, Inc. Linda and Bernard Chalfin Craig Hill George M. Murray, III Revocable Trust Priscilla and Curt Tamkin Charina Foundation, Inc. Mark Hoffman John P. Murrin Carol and Melvin Taub J. Dawn and Mark Christman Katie and Phil Holthouse Muskin Family Foundation Teco-Westinghouse Motor Company Church Street The Place for Steak Rusty Holzer The Andrew Nagel and Kent M. Thornbrugh Stacy and Richard Clark Katie and Aaron Hood David Brodsky Fund Peggy Segal and David Topper William Connelly Austin Hope Tracy and Larry Nagler Mr. and Mrs. Charles Tyler Roger Cooper David Hornkohl Robert D. Nankervis Susan and Donald Ullmann Corn Products International Pat and Shirley Howe Fund Jack Nash Charles Vosmik William Curtis Jill and Stuart Hurwitz Joyce and William Niles David M. Wah Kimberly Ann Davis Leslie Weisberg and James Hyman Julie and Scott Ohlman Dr. and Mrs. John R. Walch Mr. and Mrs. Maged Diab IBM Corporation Marlene Osthoff Beth and John Weaver Tim Disney Illinois Shotokan Booster Club Mary Anne and Jim Ostrenga Melvyn and Barbara Weiss Family Silvia and Kevin Dretzka International Precious Metals Institute Leslie B. Otten Foundation, Inc. Sheryl Eberhardt Dr. Brenda M. Ivker, PhD Parkinson’s Resources of Oregon The Harold Wetterberg Foundation Linda and Richard Ellis Family J.C. Kellog Foundation Denise and Donald Paulus Carole and Rick Wiederhorn Kathy Emmerson Deb and Tim Jacobus Barbara H. Pekow Teresa L. Wilde Nell Everman Jamakepe Foundation Peterson Foundation For Parkinson’s Janice and Alan Wingo Helen Ficalora The Joelson Foundation Justin Pines Mary A. Wintzer Jean and Richard Fiesinger Harry Johnson James and Virginia Pitts Robert Zemeckis Michele and Drew Figdor Josflo Corporation Lea and Barry Porter Fund Ruth Zinar Toby and Oscar Fitzgerald JTB International (Canada) Ltd. Mrs. Jeanne F. Coleman and Mr. Debby and Lou Flancbaum Lawrence F. Portnoy $2,500 or more Dora and Neil Kadisha Rayma and William Flint Dr. and Mrs. Mukesh Prasad Anonymous (3) Tigraw Kastenberg Nelle and John Fortenberry The William L. Price Charitable Susanna Lachs Adler and Seow K. Kek Thay Foundation Dean Adler Mark Frey Elyssa Kellerman Stephen P. Rader and Family Geraldine and Harold Alden Sharon N. Freytag Michael H. Kelson Bradley L. Radoff Steve A. Alexander Joan Frost Harris and Eliza Kempner Fund Linda and Richard Reiss Mary and Edward Allen Lori and Simon Furie Kings Oil Tools Incorporated Katherine and Michael Renoff Sophie and Alan Alpert Ronald Garriques Natalie and Brian Kirkdoffer The Rhodes Foundation Alseres Pharmaceuticals, Inc. Alan Gates Bonnie and Bradford Klein Edward Robinson Carrie and Robert Andalman Beverly and Herb Gelfand Michael A. Kolodny Sharon and Scott Robinson The Stanley and Blanche Ash Laurel and George Gerhat David A. Kovner Foundation William Rosenbaum Robert Gersh Joanne and Roger Kozberg Anthony Baer Shani and Doug Rothschild The Glen Oaks Philanthropic Fund Judy and Joseph Lamastra Baron’s Fabrics, Inc. Royal Capital Managment Elaine and Brenner Glickman Lambert Family Foundation Barbara S. Baxter Samaritan Fund Mindy and Jeff Glickman Jeffery R. Leake Bayview Foundation Harriet Samuels Lisanne and Howard Godnick Phillip E. Ledin Carolyn and Don Berger Jennifer M. Schneck Dawn and Jim Goldfarb Wallace R. and Bernice E. Leslie Evelyn and William Bernstein Manuel Schneider Living Trust Nancy Jane and Mark Goldston Memorial Fund Duncan Blair Cheryl and David Schreiner Estate of Rafael Joseph Gonzalez David and Julie Levine Family Charles J. and Brenda Block Philanthropic Fund Lynda Brecke and Rick Schwartz Camille E. Granato Family Philanthropic Fund Norman H. Levine Mark Seliger Ryan Grant Lisa Boom The Jack R. Linsky Foundation The Shack Sackler Family Joan Borinstein The George & Reva Graziadio Foundation Marshall and Carolyn Litchmann Frank Selvaggi and William Shea James H. Breay Vicki and Michael Gross Susan and Preston Lowe Jack Shenkman Trust Tyler Burke Donor Listing MJFF AnnuAL REPORT 2009 | 27

The MJFF Legacy Circle

Matthew MacGregor The Legacy Circle honors friends who support the Foundation’s work through John Magnuson bequests or other planned gifts. While MJFF’s mission has always been to put Anthony Magoch itself out of business by curing PD, planned gifts provide a major, long-term Joe Marinucci funding source that we can both plan around, and leverage immediately, to David & Susan Martin Foundation accelerate high-impact research. Joel McCleary Anne and James McCoy John L. McHugh Foundation, Inc. Anonymous (8) Estate of Martin Nash Gail Reeves McKesson Corporation Sylvia Marie Becherer Estate of Don and Ruth Palmer Judith Snow Reidel Revocable Living Trust Carole Joyce McNeil Estate of Jean Patton The Elfrieda Remlinger Richard Belman Revocable Living Trust Christopher L. Medina Estate of Marjorie Pippie Lorri Boetto Thomas Sabourin Clent Mericle Estate of Melvin Rauch Virginia Brooks Karen Schneider Elizabeth and Leslie Michelson Estate of Marjorie Richards Jock Casasus Estate of Eileen R. Salter Manuel Schneider Lee Middlekauff — Citi Living Trust Cal Chadwick Estate of Lucile Traeger Debbie Minard Sean Sidway Frederick C. Colton Estate of Melvin S. Zuckerman Brent A. Miner Henry F. Spector Frances Reser Coody in Janet and Robert B. Ettleman If you have made Beni F. Monaco memory of John Lester Coody Dorothy Strauss Jeff Evans estate plans that Mariann and Carl Morales Anne and Larry Davis The Gilbert Strong Trust Barbara Folender Shelley Olson and Rudy and Jane DiNunzio The Sutherland Family include MJFF Ramiro Moreno The Donald and Martha B. Estate of Sam Anderson The Teitelbaum Family and would like Mary and Warren Myer Geibel Trust Trust to be listed as a Estate of Lisa Susan Margaret C. Glosser Trust NBSC Baricelli-Kureen The Sophia Tomich Trust Peter Gonsalves member of The Wesley & Julie Nichols Family Estate of Helen Bennett The John D. Turkel Foundation Juan Griego Revocable Trust Legacy Circle, Estate of Ruth Carter Northrop Custom Metal, LLC The Frederick W., Norma G., Alessio and Flora Ventura please call Estate of Alma Chitwood and Janet L. Grill Family Nancy J. Novick Margareth M. Wall Estate of Catherine Ciocca Endowment Fund Karen Leies at Earline Arnold and Deryck Nuckton Dr. Brent and Terry Estate of Diane Mae Clark Andrew S. Grove (212) 509-0995, Victoria and Ryan O’Hara Weinberger Estate of Josephine M. Cretnik Thomas K. & Yvonne G. Hanes ext. 269. Doris and Thomas Parry Charitable Remainder Trust Elizabeth H. Weinraub Estate of Henry Czerwiec Diane M. Pattee Richard Henriksen The Dotha S. Welbourn Estate of Beryll Deming Charities Trust Amy and Joseph Perella Lee Herman Estate of Marjory S. Fellman The Charles C. White David Phillips Mary Hopkins Estate of Rafael J. Gonzalez Revocable Trust Sylvia L. Polen The Hoover Family Charitable Estate of Richard Gorman Kathryn P. Wright Judith Belzer and Michael K. Pollan Remainder Trust Estate of Iva Pauline Hancock Yacuone Living Trust Marla and Dean Provost Judy and Charles A. Huss Estate of Pollyanna Herrell Pugliese Family Charitable Fund The Grace Richardson Estate of Helen Hoskin Jones Trust Larry F. Randall Estate of Jack Kellogg Eleanor Frances Nelson Jordan Rainier Investment Management, Inc. Estate of John Christopher The Jerry Katz Trust Jennifer Saul and Stephen Rich Kimmey Rev. Dolores K. Kimsey The Philip W. Riskin Estate of Dolores E. Kossak Charitable Foundation Rose Krieger Estate of Louis Krieger Mr. Richard G. Robb Jr. Jim and Deborah Long Estate of Raymond H. Lake Rocking For Parkinson’s Disease Sally and Andrew Lorenz Estate of Dorothy Lesher Research Foundation, Inc. Robert G. Lusk Estate of Deb Lipton Larry Roi The Edmund Ernst Michael R. Romanowski Estate of Byron Mavrelis McClure Trust Lawrence Ruben Estate of Geraldine McMillan Elizabeth Murphy Thomas J. Sabourin Estate of Edna May Minnick Karen Oliver Susan G. Salerno Estate of May Moore The Margaret Paul Trust Kenneth R. Salling Estate of Sidney Kanz Morgan John Richard Randall Vik and Margarita Sawhney Larry Randall Brian, Maire, Aidan and Estelle Randolph Maeve Schirf Schwab Charitable Fund continued on page 28 28 | MJFF ANNUAL REPORT 2009 Donor Listing

$2,500 or more (continued from page 27)

Charles Scott Brenda and Robert Aiken Don C. Bedell Jared Brimfield Jeff Seabold Roger E. Ailes Nancy and Michael Beebe The Judy & Bernard Briskin Fund Michele and Kenneth Seim Alaska AFL-CIO Dr. Holley A. Belch Lynn A. Brody Kevin Sheehan Andrew Albert Gerry B. Belling Philanthropic Fund Ellen and Peter Brody Robert Sholty Eduardo Alcocer Peter Benedek John F. Brown Glen and Amy Siegel Michelle B. Alifanz Michael J. Bensing Lisa and Steve Brown Sills Foundation, Inc. Robert Allard Alfred K. Berg Diana Browner Linda and J.R. Sims Andrew Allen Susan and Adam Berger Keith N. Browning Family Foundation Rita Sklar Julie and David Allen Michael Bernstein Beatrice Bruce Jude and Joseph Smith Jean and Harold Allen Nancy and John Bertino Christian Bruckner Maureen and Glen Smith Jodie and George Allen Jo Anne and David Bescherer Sandra and Peter Bruhn Delores and Isaac Soffer Donald Allman Jo-Anne and Richard Bilotti Horst Brunner Solomon Family Foundation William E. Alt Charitable Fund Harvey Bird Mr. and Mrs. Steven C. Bryant Sound Sight Technologies, Inc. George Amandola Joann M. Bisto Janis and Wiley Buchanan South Valley Civic Theatre Amedisys Incorporated Kathy Blackmore Dana Buchman Margaret P. Stevenson Foundation American Endowment Foundation Clarence and Sheila Blair Beverly and James Buckley Stolper Family Trust Noni and Charlton Ames Brad Blanchard Kay and Matthew Bucksbaum Rose and Richard Straeter Nora Ammar Barbara Blanchfield Christine Bulawa Lisa and Scott Stuart Noah J. Anderson Carol and Jim Blann Otis Burdine Summit County Parkinson’s Support Annette Andrade Betty and Ray Blansett Laura Kang and Paul Burkhead Group Anne and Joseph Andrew Keith Block Emily W. Burns Sundance Running Club Penny and Marion Antonini Kristie and Steven Block Burr and Forman, LLP Ram Sundaram Nino Antuzzi Christopher Bloise Eugenia and George Burylo Dr. S. Jerome and Judith D.Tamkin Sheldon & Carol Appel Sandi and Jerry Bloomberg Lloyd Byars Lisa and Steven Tananbaum Family Family Foundation Blue Bell Foundation Foundation Celia M. Byrne Dane Arden John and Myrna Blume Tarshis Family Foundation The Harman Cain Family Foundation Jody and John Arnhold Dr. Maxwell L. & Florence C. The Adam USDAN 2006 C.L.A.T Brendan Callahan Courteney Cox-Arquette and Blumenreich Foundation Carol S. Callahan The Kallis Family Charitable David Arquette Boar’s Head Brand Cassametta Foundation Barbara and Roger Calvert Sharon Asher Provisions, Inc. Elizabeth and Dennis Tito Donald Cantway Audio Command Systems, Inc. Bobbo Jetmundsen Foundation Gail and Richard Ullman Elaine and Elliott Caplow Austin Community Foundation Bock & Associates, LLC Meredith and Bryan Verona The Caravan Trust Auto Club Speedway/ David Bohnett Judy Wada Ms. Gillian Zucker Sandy Carey Robin Bond Sally Washburn Avad, LLC Ian T. Carnathan Joseph F. Boulos Anne and William Washychyn The Bacas Family Foundation Donna Carpenter Francois Bourret Bradley J. Wechsler Shae Baddour Cheryl and Steven Carver Scott Boxer Norma and Ed Weinman The Arnold F. Baggins Foundation, Inc. Casey Family Advised Fund Tom and Leann Boyan Linda and Patrick Welch Lori Pollan and Allan Bahn Peter Catalano Mark Boyd Diane Wilsey Anne B. Baker Dawn and Rocky Caullwine Norm and Linda Boyer Jan and Eddie Woods Anne Elizabeth Baker Barbara and Anthony Celeste Marcia and Dennis Brager Billy Wooters Pamela and Jesse Baker Centre Reinsurance David S. Brammer Ken Wormser Leslie and Buck Balkind Sara and Joe Cerrell Shirley and John Bandy Mr. and Mrs. Wayne R. Zdenek Paul C. Baria Jacquelyn Chandler Dwight Brannon Jeannie and Terrence Lee Zehrer John J. Barry Robert T. Chang Brenda and Robert Brantley Linda and Douglas Bartlett Charitable Foundation Trust $1,000 or more Braude Foundation Steve Barton Charitybuzz Anonymous (18) David B. Breed Michael Bartsch Carol Chase Nancy and Colman Abbe Janet M. Breedlove Lee Bass Lance H. Chau Denise and Herb Abrash Daniel Brewer Mickey Bass Alfred Checchi Jorge Acquaviva Bricker & Eckler, LLP Kathleen C. Bassi Marissa and Saj Cherian Aeroquip Credit Union Bridgewater Associates, Inc. Jerome Simon and Hilary Bates Harry Chernin Foundation Aggressive Heating, Inc. Nicolas Brien Beach Equities Helena Christensen Agron, Inc. Devon and Peter Briger Lisa and David Beall William Christie Donor Listing MJFF AnnuAL REPORT 2009 | 29

Steven Chrzanowski Michael De Jong Elizabeth Ernst Leslie and Morton Gerson Chubb Corporation Susan M. Delago Atilla Ertan Steven Gerstung The Chutorian-Semler Family Gilles and Inge Dellaert Drew Ertman Lisa and Rick Giacco Foundation Maureen and Robert Deloury Judith and Irving Evall Suzi and Steve Gilbert Pamela Cincotta Paul D. Delva The Evslin Family Foundation Deborah and Donald Gill Circle of Service Foundation Robert Denlow Tom Ezaki Michael Gillen Gary Cirilli Sarah and Paul Densen Ramsey Fadiman Mike Ginsberg Ciuni & Panichi Advisors Charitable Foundation Scott Fahey GlaxoSmithKline Robert C. Clare Ginny DePasqua Fairwood Financial Services, LLC Shirley Gleich Claremore Club, Inc. Robert D’Eustachio Darby and Jason Farmer Kathy and Robert Glickman Erin E. Clark Kimberly Dewalt Peter Farmer Justin Gmelich Sacha Clark Charles Diamond Stephen E. Farris Stuart Goldblatt Clayman Family Foundation Jerry Diamondstein Fasnacht Family Foundation Mitchell and Lenore Goldstein Marlynn K. Clayton Richard Dickstein Dennis R. Fay Barbara M. Goodbody Judi and George Clute Linda K. Dieken Bunny and Sy Feigenbaum Sandra and Allen Gookin The Coffee Bean & Tea Leaf Jennifer and Royce Diener Joan and William Feldman Mark Gordon Louise and Thomas Coffey Steve DiFillippo William Fellows James and Meg Gordon Abe M. Cohen Family Foundation Distort, Inc. Fidelity Charitable Gift Fund Judith and Sheldon Gordon Jeff Cohen Don P. Dizon Albert L. Fierro Sr. Charitable James and Penny Gorman Dena and Steven Cohen Jody Dobrowski Foundation Irwin Gotlieb Mr. and Mrs. S. Michael Cohen Joseph Dorsey Esther Baird and Stanley Fimberg Thomas Gottlieb & Carol Kirsh George F. Cole Karen and Christopher Downie Magdalen Fisher Family Fund Tracey and Adam Collins Clorinda R. Driscoll Peggy and Dick Fitzgerald The Gould-Shenfeld Family Foundation CommerceNet Jesse Du Bey Andrew Fitzgerald and Richard The Grace Jones Richardson Trust Fitzgerald Competition Corvette Association Patty and Howard Dubin Grand Temple #15 Pythian Sisters NYC Incorporated Timothy Fitzgibbons Michael Dubin Grange Kitchen and Bar Compulink Business Systems Ilene and David Flaum Stephanie and Brian Dubinsky Alison and Andrew Gratz Susie and Butch Conen Maria and Raymond Floyd James M. DuBois Mr. and Mrs. Bennett Grau John C. Conwell The Ellen M. and Lawrence B. Patrick and Mary Dunleavy Erica and Kenneth Grau Cooper Sheet Metal Floyd Family Foundation Dr. and Mrs. Paul P. Dunn Marisa and Edward O. Green Debi Corbin Deirdre Flynn Marsha and Anthony Durniak Zoe and Steve Green Anita Cosgrove Kenny Foo Marvin and Jean Durning Theodora and Robert Greenbaum Laurel and John Cravens The Ford Family Foundation Kris Dworkoski Sandy and Irwin Greenberg Mrs. Joan Creedon Mary Ann Forman Robert Dworkoski The Martin B. Greenberg Foundation Jeanne and Peter Crisci Amy Foster The Dyer Family Sheila Greenberg Jeremy R. Crisup The Connie Frank Foundation Carole and David Ebner Nancy S. Greene CWS Apartment Homes, LLC Bruce and Kipp Freeman Stanley Ebner Greenlight Foundation Louis Dahan Katherine Frekko The Economist Newspaper Sherwin Greenwald Dalio Family Foundation, Inc. Andrew and Brooke Friedman The Edgecomb Foundation Donald E. Greenway Jan Dallam Edna Frigo Adele Eger Sharon Gregorcyk Kumaran Damodaran Judge Hilda R. Gage Ronald Eger Edward W. Griffin Memorial Fund Diane Danakas-Discoe Roy Gagnon Marty and Dale Ehrenreich Clark Grimm Katherine and Costa Darras William Gaine Mitzi & Warren Eisenberg Glenn Grossman The David Family Foundation Family Foundation Jane and Robert Gallagher Deborah and Allen Grubman Nancy and Russell Davidson Mrs. Ethel Eisenberg Patricia and Lawrence Gallaway Kevin Gruver Ellen and Gary Davis Bruce W. Elder Gans-Mex, LLC Charlotte and Larry Gustavson Joey Davis Gail and Jim Ellis Richard Garber Robert Haber Scott Davis Lisa and Christopher Engel Ken Garschina Cindy and James Hadaway Kathryn and Stuart De Haaff Charles Engelke and Jerry Geldernick Barbara and Ed Haddad Elizabeth de Ramel Laurie White Fund Mary and Peter Gens Mallory and Peter Haffenreffer Dick Deery Richard England Pat and Charles Genuardi Lia and Bruce Hager Karen and Carl deGraaf Joann and Wayne English George Weintraub & Sons, Inc. Ginger and Larry Hahn David Deibel Rodney English Marilyn Gerber Amy and David Halliburton Ross Epstein Joan L. Germany continued on page 30 30 | MJFF ANNUAL REPORT 2009 Donor Listing

$1,000 or more (continued from page 29)

Halperin Foundation Robert Holo Stephen and Laurie Kafka Yvette and Roger Kotch Jeremy Halpern Samuel and Hannah Holzman Trust Kahn Foundation Selma and Eldon Koznek Don and Mary Jane Hamaker Honey Farms, Inc. Robert J. Kahn Foundation Mitchell Kramer Rodney N. Hamilton Keith A. Hoover Richard Kaminsky Elaine Kranich The Hamilton Foundation, Inc. Mary Hopkins G. Kanda Seth Krauss William Hamm Joan Hotchkiss Thomas Kandel James Kress Andrea and John Hampshire The Mary L. House Charitable Gifts Stephen F. Kaney Carole and Hal Kroeger Rita Wilson and Tom Hanks Lina Hu Sally and Paul R. Kanin Lisa and Clyde Krogh Rochelle Hanna Hub International Northeast Limited Carol G. Kaplan Beth and Williams Krumbein Stan Hannah Carol and Frank Huber Ruth and Jess Karter Kevin M. Kruszenski Trish Hanson Leane and Gerald Huchital Karen Katen Foundation Kucera Family Foundation Harbor Casino Bar Restaurant, LLC Paul Huchro The Jerry Katz Trust Jon Kully Eric Hardesty Hudson Housing Capital, LLC Beth and Brett Kaufman David Kurti Judy and Joseph Harding The Huisking Foundation, Inc. Andrea Kay Randye and Brian Kwait Susan and Richard Hare Family Derris and John Humphrey Lauren, Dave, Brady and Reagan Kay Lake Forest/Lake Bluff Junior Foundation Juanita C. Humphrey Bryan and Meg Keen Women’s Club Ethel and Samuel Harmatz Elizabeth Hunter Gina Keenan-Heepke Mary Lou and Bill Lange Harmon Family Trust Ryan Huskey Douglas Kegler Chriscinda and Fabian Lange Ron Harner Judith and Charles Huss Joell and George Keim Guy Langevin The Harnisch Foundation Holly and Thomas Huth Yvonne Kellar-Guenther Diane and Jerome Lapham Harper Collins Publishers I Do Foundation Katrina and Pat Kelley Patti and Thomas Larkins Jeremiah T. Hart Leonard Iacono Jed Kelly Pamela and Erik Larson Brenda Harter ICAP Services North America, LLC Mary Kelly Jan and Fred Laughlin Kristy and Rob Harteveldt Independent Bank Arline and Robert Kennedy Laurel Conqueror 451 Harvard University David B. Ingrey Sara Kenny Laurel Conqueror Association, Inc. Michelle and Hugh Harvey Smoller Scholarship Fund Sharyl and Roy Inlow James M. Kerr Peter and Tina Hayward Verna and Neil Laurin Lesley Innes Dana and Richard Kind Linda Elizabeth Hazen Endowment Bonnie Englebardt Lautenberg International Precious Metal Dr. Betty R. King Fund Institute New York Joe Lavi Kings Drug and Surgical Robin and Daniel Hedlund Clifford W. Ishmael James E. Lee Kings Park Slope, Inc. Andrea and Ron Hein Charitable Fund ITG, Inc. Debra Perala and Robert Lemon Scott Kingsley Jeff Heitzner Valerie Frost-Atkins and Len Camber Grantor Trust Shawn Kingsley Betty and Irwin Helford Robert Iverson Charles and Margaret Levin Family Michael Kinney Cathy Duffy and Frank Heller Larry Jacobson Foundation, Inc. Margie and Weldon Kirby Robert Helsgott Linda and Denny Jacobus Family Wendy and Barry Levin Rebecca A. Kirk Andrej-Nicolai Henkler Marc and Karen Jaffe Becky and Mark Levin Laurie C. Kissell Lee Henson Sheryl L. Jedlinski The Richard L. Levin Family The Kenneth And Laurie Kissell Foundation James and Marjorie Herald The Sidney D. Jeffe Trust Charitable Foundation Lola J. Perniceiaro and Mark A. Levine Debra Hernberg Sheila Jefferson Leonard Kleiman Elayne and Howard Levkowitz Jim D. Herrgesell Suzie and Max Jellinek Matt and Susan Klein Edward and Jami Levy Foundation Maureen and Michael Hess Michael A. Jessee Valerie Klein Peter Li David Hidalgo, M.D. Jewish Communal Fund Barbara and Leonard Kolod Jillian Libenson Peggy and Richard Hieter Jewish Community Foundation The Donald C. and Norma Seth Lieberman High Five Foundation Barbara and Mike Johnson (Klug-French) Allyn Fund of the Anita and Stanley Liebowitz The Hill Family Charitable Foundation Carol Johnson Lutheran Community Foundation Fred W. Limbach Hillard Farber & Co., Inc. Elaine Joost Gisela Knijnenburg Karen and Mark Limbird Susan E. Hillery The Jordan Company, L.P. Kevin Koch Pam Lindroos Linda and Mike Hinkle DeNine and Robert Jordan John N. Kogan Stuart Liner Judith E. Tschirgi and Steven J. Hoch Steven R. Jordan Marguerite and Morton M. Kondracke Annette P. Lintz Kay and Grey Hodnett William H. Josephs Norman Konner Paul F. Little David L. Hoffman Sheryl Josephson Elizabeth and Ken Kopelman The Litwin Foundation Laurie and Matthew Hogan Matthew Joy Paul Korman Linda and Robert Livingston Greg Holden Dr. Scott Kadlec Mary Beth and Robert Kors Local 147 Tunnel Workers Sharon Kaelin Scott Koster Donor Listing MJFF AnnuAL REPORT 2009 | 31

2009 Matching Gift Companies

Adele F. Loeb Abbott Laboratories, Employee JPMorgan Chase We are grateful Giving Campaign Arnold S. Loeb Keefe, Bruyette & Woods, Inc. to these Aetna Foundation, Inc., Partners Erin Loebner Kraft Foods Foundation Matching in Community Giving Gifts Program companies for Andre Longpre Allstate Giving Campaign KTLA-TV their generosity Mark Loreno American Express Foundation Company Lone Pine Capital , LLC in matching Antone and Deborah Lott Employee Giving Campaign Lumina Foundation for Education Loyal Order of the Moose America’s Charities, Inc. employee gifts to The McGraw-Hill Companies Karen and Michael Luce Ameriprise Financial Employee MJFF, resulting in Employee Giving Campaign Michelle Luethy Giving Campaign a total match of Merck Partnership for Giving Lynn H. Lullo Ameriprise Financial Matching Gift Program Merrill Lynch & Co. Foundation, Inc. about $200,000 Diana Lum Matching Gift Program The Amgen Foundation in 2009. Evan Lundin Microsoft Corporation Matching Anheuser Busch, Inc. Michael And Louise Lynch Charitable Gift Program Bank of America Charitable Foundation Foundation, Inc. Morgan Stanley Bank of America United Way Campaign Nancy and Thomas Lynch Mutual of America The Bank of New York Mellon Amy and Brian Maas National CineMedia, LLC Community Partnership John Mack Carter, Sr. Nestle Foundation Bank of the West Sue and Todd Mackey Pepsi-Cola Company Bill & Melinda Gates Foundation Nancy Macklin Pfizer United Way Campaign The Black & Decker Corporation Madison Avenue Pharmacy Portland General Electric Company Boeing Company Employee’s Melody and Chris Malachowsky Community Fund The Prudential Foundation Matching Gift Program Charles Malk Bristol-Myers Squibb Company Michael Mandel Employee Giving Program The Robert Wood Johnson Foundation Mike and Sallie Manning The Capital Group Companies Sabre Holdings United Way Campaign Charitable Foundation Marawood Construction Services Sanofi Aventis Matching Gifts Program Cardinal Health Foundation, Inc. Patricia Marinilli Takeda Pharmaceuticals Employee Chubb & Son Giving Campaign Markit North America, Inc. Coastal Georgia Combined Tri-State Health Association Marlette Family Foundation Federal Campaign Incorporated Linda Marlowe Davis Selected Advisers, L.P. UBS Foundation USA Matching Gift Program Joanne Marqusee Dell Direct Giving Campaign United Way of Alabama Sonya Marsden and Employees Charity Organization Elsa Marsden United Way of Allegheny County Employees Community Fund of the Barbara E. Carr and David Marsh Boeing Company United Way of Delaware Heather J. Marsh Evanston Capital Management, LLC United Way of Greater Twin Cities Margaret and Robert Marshall The Ford Foundation United Way of New York City Joni and Stephen Martino Matching Gift Program United Way of Somerset County Craig Martone GE Foundation United Way of Southeastern Regina and Fred Marvan Give With Liberty Pennsylvania Marcia S. Massee GlaxoSmithKline United Way of the Bay Area Diane and Richard Mason Global Impact United Way of the Columbia-Willamette Dustin Matthews Goldman, Sachs & Co. United Way of Tri-State Matching Gift Program Juanita S. Matthews Valley of the Sun United Way Google Susan Matthews Verizon Foundation Greenlight Capital, Inc. The Philip F. May Charitable Gift Fund Washington Mutual Employee Harvard University Giving Program Robert W. May Hewlett-Packard Wellpoint/Unicare Associate The J. Robb Mayo Charitable Trust Giving Campaign Honeywell Hometown Solutions Nora and Ed McAniff Wells Fargo Community IBM Employee Services Center James McCarthy Support Campaign Independent Charities Of America Docie and Larry McCormick XL Reinsurance America, Inc. ITW Foundation Jack McCrory John Hancock Financial Services, Inc. Phyllis McDonald Johnson & Johnson Family of Companies Thomas McGee Matching Gifts Program Jane and Ray McGowan continued on page 32 32 | MJFF ANNUAL REPORT 2009 Donor Listing

$1,000 or more (continued from page 31)

Chris and Linda McKenney Marlene H. Murtonen Sandra and Norman Pessin Harry and Verna Richardson The McKinney Charitable Trust Richard Muscio Nancy Peterson Joseph Richter Peter McKown Thomas C. Muse Susan Toeniskoetter and Daniel Norman & Myrna Ricken Petree Charitable Trust Michael B. McMahan Kary and Gary Myers Carrie and William Petty Barbara and Craig Robbins James J. McNasby NAMSB Foundation, Inc. PG Productions, LLC Virginia Robbins Mary McNaught National CineMedia, LLC Rosalind and Edward Pineles Susan and Robert Roberts Joseph M. Meaden National Madison Group, Inc. Pittman Family Foundation Sandy and Mark Robinson Medicus Foundation Michael Naumann Pivot Architecture The Martin and Ellen Robinson Hedy and Benjamin Nazarian Mary Meeker Charitable Fund The Plymouth Rock Foundation Margaret and LeRoy Negus Christopher Mellen Family Fund Nicholas Roccanova Louise Poelzer Merle and Leonard Nelson John C. Mendillo Family Laurie G. Rocha Ann and Peter Pollack Foundation, Inc. Richard P. and Faye Nespola Jack Rodin Sue and Fred Menowitz Charitable Foundation Pond Jumpers Joao Rodrigues Rosellen and Barry Mensch Mary and Alexander Navab Elaine and Henry Pope Jr. Margaret and John Roever Charles E. Mensing New England Research and Carol A. Porter Management, Inc. Larry Rogovein Mary Meola Marc Porter Jullie and Garry Rollins Newark Asphalt Corporation Poudre Valley Health System Annette Merle-Smith Charitable Fund Sally Nichols Foundation Betty and Robert Mero Meg and John Rosecky Joan C. Niedfeldt Debbie, Rick, Ashley and Patricia A. Merrill Jeremy Powell Alex Rosello Anne and Thomas Niesen Bruce Meyer Philip Press Scott Rosenburg Jeffrey M. Nobel The Meyer Family Fund Anthony and Jeanne Pritzker Eva Yarmo and David Rosenthal Ann and George Norris Micanopy Area Chamber of Family Foundation Mitchell Rosenthal Commerce Virginia W. Norris Tony Proctor Tibby and Abby Ross Fran Middleman Richard Nunnelley Dina and Douglas Propp The Rothfeld Family Foundation Susan Bartsch and Robert Mileti Kristy and Eric Nuttall Gail Propp Melissa and Matthew Rubel Brian Miller Ruby and Jack Obenauer Marc Puich Steven G. Rubenstein Janice Miller Edward O’Connell Mr. and Mrs. Thomas W. Terry S. Newman and David B. Brenda and Budge Offer Steve Miller Purcell, Jr. Rubin Charitable Fund Kit and Roger Olen The Miller Family Fund Teri and Randall Putnam Robert N. Rubin Stephen Olentine Joanne McElligott and Douglas Kelli and Allen Questrom Ellen Rudman Millett Madeleine D. O’Mara Sandra and Darrel Quick Senator Warren Rudman Missionfish-Polf Toni Oosting Stephen G. Quill The Brenner Rudman Phillip Mitteldorf Minna and Duncan Orrell-Jones R.S. Quality Products, Inc. Charitable Trust Andrea and Michael Mohr Gerald Ouderkirk Stewart Rahr Ruppel Lee Family Foundation Shelly and Frederick Molineux Robert Ousterhout Lisa and Jim Ramsay Michelle and John P. Russo Phyllis Molyneux Oxford Industries Foundation Karen L. Ramsey David Sack Sarah Orsay and Russell Patricia and Stephen Paddock Kathleen and C. Dean Rasmussen Leslie Sack Montalbano Timothy Paisley Adam Ratica Stephen Sacks Ann B. Moore Palm Bay International, Inc. Robert Rau Michael E. Sadres Olga and Thomas Moreland The Pampered Chef Raymond Benner Living Trust Sage Software, Inc. David E. Morey Chester Panek Mary Reaske Elizabeth Doyle and David The Moroze Family Fund Saltzman Paramount Capital Group Andrew and Monique Dwight and Susan Morrow Katharine and Bret Parker Rechtschaffen Troy and Connie Salyers Lou Moskowitz Clint Parsons Angie and Steve Redding James and Janet Sammer Tim and Emily Moulton Pat Boone Foundation, Inc. Sharman Reecher MaJa Kietzke and Anthony MSR Advisers, Inc. Sanchez Florence H. Pattee The Reichert Foundation John Mullen Dave Sankey Frances Paulsen Kurt Reinsberg Philanthropic Fund William A. Mundell Jack Savely John and Gail Payne Charitable Barbara and Paul Reitzin Wendy Munger Kenneth Sawka Gift Fund Jack Remnet Maureen Ocallaghan-Murphy and Linda Sawyer Steven and Nancy Payne Fund Eileen Rencher John Murphy Scars Into Stars Charity Amy and Brook Payner The RFP Fund, Inc. John D. Murphy Joshua Schechter John P. Peavy Jill and Scott Rhea Mark Murphy Schechter Foundation Peerless Clothing International Dave and Lori Rhodes Mary Murphy Harry and Lila Schiffman Faye Pender Irene Hegeman Richard, MD Donor Listing MJFF AnnuAL REPORT 2009 | 33

Suzette and Jay Schochet Fritz Eric Sperling Jr. Jean M. Trainor Westlake Golf and Country Club Luci Schofield Lynne and Eric Spillman Traub-Brittan Family Foundation John R. Wherry The Jean and Thomas Schreiber Justin Spitzer Terry Tribolet Grace and Glenn Whitecotten Philanthropic Fund Don Springer Tri-State Health Association Mary and Rick Whiting Incorporated Nina and Paul Schroder Eric Sprunk Whitlock and Associates Susanna and John Trittschuh Schulman Family Foundation Simon Stanlake Mary E. Whitworth Linda B. Trugman Judith and John Schumacher Dan Stark James Wicker Todd D. Turnidge Marc Schumann Dennis and Janice Steindler Elisha Wiesel Jane and Wat Tyler Mark Schupack Drs. Susan and Robert Stephens Daniel Wilkins Lisa Tyson Mary and Richard Schuster Adam Sticpewich Brett, Jack, Charlotte and Unifrutti Of America, Incorporated Cricket Wilkinson Susan Schutzman Dana and Andrew D. Stone United Way of the Columbia- Donald E. Will Teresa and Daniel Schwartz Jacquie L. Strauss Willamette Dale Williams Meryl and Jeff Schwartz Marie Strebel Nancy and Chris Unrath Michelle and Zach Williams Walter A. Scott Jennifer and Chad Streit Victoria and Walter Van Den Burg Lynn Wilmas Georgia L. Sebek JoAnna Strizic Sally Van Dyke Allen Wilson Raquel and Andrew Segal Amelie Stroh Loren K. Vanderslik Murray John Wilson The Selkowitz Family Foundation Eric Strom Vector Search Group Pete Wilson Ambassador and Mrs. Mel Sembler Harvey and Susan Stromberg Nicole and Michael Vermut Daniel Wistran Karen and Samuel Seymour Peggy Sturman Hope and John Van Beuren Joel S. Wojnilower Sara and Mark Shacket Marianne Sufrin Van Wagner Communications, LLC Meredith Wolff Marjory and Jeffrey Sharp Gary Suttle The Peggy & Ellis Wachs Clifford A. Sheets Wolters Klumer Health Georjean Sweis Family Foundation Marti M. Shell World-Wide Holdings, Inc. Fund Anne and Alan Taetle The Wagner Family Foundation Pauline and Alex Shender Robert D. Wortzman Kathy Taggares Valerie Wagner Martin M. Shenkman Revocable Trust Gerald Wright Karen A. Tamburlin Wakefern Food Corporation Marilyn and Rex Sheppard Jennifer and David Wroan Edward Taran Fund The Morton & Lillian Waldfogel Brooke and Brett Wyard John H. Ship Lynne Tarnopol Charitable Foundation Jean Yee Debbie and Steven Shough Nancy and James Taylor Suzanne E. Walsh Wanda and Charles Young Rose Betty Short Nancy and Mark Taylor Charlie Wancio Peggy Katz and James Young Judith M. Shutz TCA Bannockburn, LLC Mary and Jack Ward Mary Ellen and Jim Young The Sidewater Family Foundation, Inc TD Bank William Warden Fei and Wei Yu Wendy and Stephen B. Siegel John Teeger Theresa and Bradley Warnecke Larry S. Zajdel Sierra Microwave Technology, LLC TEM-PACE, Inc. Jason Warner Loreen Zakem Ben Sihota Helen L. Temple David And Phyllis Warrick Fund Lois and Andrew Zaro Mr. and Mrs. Steven Silver A. Thakrar Phyllis J. Warrick Craig Zinserling David Sims Cindy and Robert Theberge Washington Trust Company Daina Zivarts Gale Single Lisa Thenell Gayle F. Wasserman Denice and Tom Zucca Jane and Steve Sinton Third Horizon Foundation Wasson Family Aaron Sirulnick Mary and Homer Thomas Richard Weber Sanford Sirulnick Michael Thomason Wechter Financial Services, Inc. Bridget Sisson Michael Thompson Eliot and Beth Wegbreit Susan P. Sloan Michele and William Thompson Sheila and Edward Weidenfeld Paula and Charles Small Rose Thorne Julie and Peter Weil Derek Smith Frank and Margaret Throssell Fund Christine Kelly and Morton O. Weinress Dione and Joseph Smith Tiarks Elaine and Melville Weiser Piper and Roger Smith Gail Tomberg Eleanor and Norman Weiss Samuel A. Smith Mamie Tompkins The Roberta and Allan Weissglass Foundation Sydell and Ira N. Smith Catherine Toomer The Adam J. Weissman Foundation Kristin K. Snow Jack and Berte Toppell Family Jacob Solomon Foundation Sharon and James Welty Lisa, Jared, Jake, and Mitch Solomon Bruce Towler Jane Wenner The Solomon Group Allison Townsend WesBanco Scott F. Sonkin David Westerman 34 | MJFF ANNUAL REPORT 2009 Donor Listing

2009 Tributees

Donations Ellsworth J. Abare Robert D. Bruce Robert G. Deloury Melvin Gerber Lo-Ching Hua have generously Martin Abel Robert Buchanan Rocco J. Demilio Joseph P. Gibbons Bertha J. Humpery been made Fabrizio Acquaviva Edward Burke Lorraine DePompa Jan Gibson Arthur L. Humphrey in tribute Margaret E. Allen William O. Burnett David F. DeWaters Joseph W. Gibson John R. Humphrey Martha L. Allen Jerry R. Burns Marina J. Dewey Jack Giesecke William H. Hyde to the following Sara G. Allen Barbara C. Calvert John A. Dieken Bob Ginsberg Frances V. Ireland individuals and Dave Alpert Janice Campbell Manuel V. Diez Albert B. Glickman Dave Iverson organizations. Mark L. Amoss Minnie Cantor Rudolph DiNunzio David Glickman Philip R. Jamison Eleanor H. Ancona Ross M. Canty Mary C. Docherty Judith Glickman Joseph S. Jankovic, MD Samuel M. Anderson George W. Carpenter Charles Doering Sandra Gluck Alberto Jimenez Jerald L. Andrew Robert M. Carriger Alex Doolas Esther Goldberg Charles L. Johnson Paula P. Archinaco Patrick A. Caruso Roger Durban Sheldon Goldstein Gerald L. Johnson Joseph P. Armao Barbara Carver William Dusterhout Margot Gosen Rhona B. Johnson John E. Arnet Margaret W. Caullwine Thomas D. Ebner David A. Graffam Freeman P. Jordan Ian Arons Elizabeth V. Cavano Lois A. Elander Lafayette M. Gravely Julia Jordan Tim Ashe Vincent Celenza Anne-Cecilie Engell Speyer Rhonda L. Greear Mary Kamal Louis W. Astorino David Cerrina Thomas English Dorothy Greene Delphine Kaminski Mary Athanas Josephine Cerrina Morris L. Estess Elliott S. Greenspan Amalia S. Kaminsky Robert Audette Joyce Chalnick Everyone at Rock Steady Matthew Greenstein John E. Kandel Boxing J B Chinghwa P. Chang Curtis L. Greenway Larry E. Kandel Everyone with Parkinson’s Marian L. Badendieck Elizabeth A. Chase Disease Rosa L. Griffin Marshall A. Kaplan William H. Bagot Arthur A. Checchi Dorothy Evslin Grace S. Griffith Maurice Kaufman Woodrow H. Baker Wes Christie Anne Eyes Carl Grossman Ernest Kellar Paul Balerud Ronald T. Chung Ralph P. Fader Fred W. Grotophorst S. Arliss Kemp Shirley Bandy Jeanne A. Clare Jack Famularo William A. Gruy Violet M. Kent Bettye Baria Patricia Clarke Jeanne H. Faulkner Paul Gustavson Clifford R. Kesler Gerald Basie John W. Coffey Natalie H. Fay Cindy Hadaway John W. King Frank M. Bass Barry J. Cohen Albert L. Fierro John S. Hager James C. Kirk Arlene M. Bauer Louis Cohen Karen L. Finerman Sylvia Harman Mary L. Kissel Richard Beck Richard Cohen Emanuel Finkelstein Ramona A. Harmon Mary L. Kissell Shirley R. Belch Howard Cohlan Patrick Finnegan Kermit Harner Eugenia Koog Thomas H. Belt Gerald F. Conlin Richard H. Fitzgerald Stanley Hart Frank Kotch Raymond Benner Joseph E. Connor Ronald H. Fitzsimmons William J. Harte Edward W. Kowalczyk Jerry Bernstein William Conroy Earle R. Flesher William Hauf Selma I. Koznek Judy Bernstein John B. Cooke John L. Flowers Susan B. Haverstock Barbara Kraly Shirley C. Berryessa Hiram L. Cooley John J. Foley Leo E. Helander Clyde L. Krogh Howard Bidwell Denise Costa Manuel Forman Jerome Helgren Robert Kroupa Lois Binder Lucien J. Cote Julian F. Forthofer Anita S. Henry Renee Kumetz Janet Blazon Robert Cowhey Lawrence E. Forthofer Patrick Henry Gerald T. Kurtz Gary R. Bloom Don Crisup Michael J. Fox Dena Herema Bonnie Kutas Eugene J. Boros William C. Curtis Charles Frantz Michelle Hespeler Dirk A. Kuyk Michael Bosse Linwood Custalow Theodore Frazis Patricia C. Hester John N. Lam Freida Boujoukos Dad Helen Fronstin Leonard F. Hill Bernard C. Lamas Sharon Boyd Antoinette R. Dalo Daniel B. Frost Naomi Hoffman Michelle D. Lane Francis B. Bracken Joseph A. D’Anna Cynthia Fucci Robert B. Holland Selma Lanes Jack Breed Rex Davis Richard Garber Jim Holt Robert E. Larson Susan B. Bressman, MD Susan M. Davis Joseph A. Garraffa Katie Hood Elliott Latez Lisa Brodsky Glenn Davis-Anacker Natalie Gasior Richard E. Hoover Robert F. Latimer Robert M. Brody James N. De Haaff Abraham Gaslow Sarah K. Horn John J. Laureto Marie Brooks Victoria Dean Paula Gaston Warren Hottenstein Neil Laurin Janet L. Brown Donald H. DeHayes Patricia Gateff Doris J. Houser David M. Laushey Donor Listing MJFF AnnuAL REPORT 2009 | 35

Stephen Lawrence John J. McNamara James J. Peters Jerome A. Sertick Colburn R. Thomason Megan Layer James W. McTague Jim Peterson Robert W. Shackleton Andrew Tobias Sylvia M. Lazar Robert G. Meelheim Richard T. Peterson Paul R. Shalita Jack Toppell Wanda M. Leach Richard L. Meirink Homer E. Pfefferkorn Ruby Shepherd William Torresi Merle Leake Mike Meltzer Raymond E. Pittman Jerome P. Shifter Judith A. Towler Joy Leichenger John C. Mendillo Albert B. Polen Yaeko Shintani Jennifer Trittschuh-Valles Roland H. Leisy Barry Mensch Stephen M. Pollan Joanne Ship John R. Twiss William B. Leonard Lavonne S. Mensing Joel Portnoy Debbie Shough Miller H. Ullmann George Lerman Scott Meril Jack M. Posen Georgina Silva Martin B. Unger Martin Levin Cora Messinger Lane D. Powell Evelyn Simon Alvin Vanderslik H. Burton LeVine Joyce A. Metcalf Joel Press Melvin Simon James Vaugh Gustave L. Levinson John R. Meyer Dolores M. Princiotta Alexander M. Sinclair Virginia Norris’s Mother Arnold Levy Patricia Michaels Robert Pritzker Merle E. Singer Thomas A. Wagner Edwin A. Levy David O. Miller Charles H. Pulley Frederick J. Sisson Irene Wakabayashi-Yanaga Linda Avey’s Father Leo Miller Sue B. Pye Mary E. Skewes Sharon Walker Ariel Linden Shirley Miller Thomas B. Ramsey Charles Sklar Anthony W. Walsh Arthur E. Lindroos Jewell O. Mohn Gary L. Randall Leo J. Sklar Antoinette Warden David F. Lindsley Jerry Moore Richard Randall Patricia A. Sloan Stephen D. Weinress Gerhard D. Linz Monica Morekin-Serfas Theodore M. Ratica Edward Smallwood Leona Welty Jennifer Lipschultz Thomas P. Morrissey Kenneth A. Reecher Clare D. Smith Stephen Welty Marc S. Lipschultz Mary C. Murphy Kevin Reilly Guy H. Smith Annette Westerman Val Livingston Thomas P. Murphy Margaret M. Rhea Hugh P. Smith Bill J. Whitworth Barbara Lizerbram Wilma M. Murrin Roger J. Rice Ira N. Smith Richard J. Wiederhorn Richard Locke Donald J. Murtonen Jacqueline Richard Princie L. Smith Earl Wiener Jim Long Cheriyath Nath Deborah Ridel Sandra M. Smith Jack Wilco Delores Loreno Noel Nathanson Antonio Rimanelli Martha Snow Samuel A. Wilkinson Donald N. Lykens Susan Nathanson Robert E. Roderick Mary L. Solema David R. Williams John T. Lykouretzos Maurice R. Nazareth Sonya Rodin Judith C. Spencer Linda Williams Fred Mann Robert G. Neale Jean Rooney Emily Spiegel John S. Wilson Michael J. Manning Ron Nelson Richard M. Rothenberg Jerry Spiegel Elsie Winn Elena Manno Joseph D. O’Brien George W. Rourke Ann K. Spier William H. Winston Ellis L. Marks Catherine S. O’Connell Judith F. Rubin Jack Spillman Mildred Wise Ralph H. Marquet Mary L. Ostrowski Josef Ruepp Warren E. Sprague Sue Wojnilower Robert Marvan LaVonne Pagelow Helen Runnels David Steen Marty Wolff Harry Maunu Donald G. Paige Alfred G. Russell Ray Steinman Dorothy M. Yares Marilyn H. Mayer Mary A. Palmer Kenneth B. Russell Susan A. Stephens Barbara P. Young Teddy Mayer Muriel J. Parmenter Hans Salomon Donald J. Stewart Charles W. Young Mitsuko McCandlish John Paron Harry Salter Harry J. Stingley Miriam Zaretsky Ida L. McClure Hillery A. Parrack Jessie Santini Stanko S. Stojkovic Marta Zivarts Sean McConnell Robert W. Patin Edith Saunders Howard M. Strauss Iva V. Zucca Cleo McCroden Narhari Patolia Shiv L. Sawhney Mary G. Strazz Seymour Zwerin Rosemarie McCrory Joseph C. Pattee Giuseppe Scattone Edward A. Strebel Kathy McCune James H. Patterson Helmut M. Schaffler Robert F. Streit Thomas J. McDade Anne Paykos Carolyn Schenker Joseph J. Strizic E. Janet McDonald David H. Peery Gail Schmerl Shirley Stroud Edward McGah Claiborne Pell Richard L. Schneider Eva Stuenkel Mary Etta McGaughey Harold D. Pendergraft Thomas M. Schroeder Arnold L. Sutta Patrick T. McGowan Robert E. Penny Margaret M. Schuman Craig Swanson Carol R. McGuire Ruth Perrigino Elaine W. Schuster Paul Swanson Louise McLaren Mary B. Perry Frank G. Sebek Robert O. Sykes James D. McMahon Norman H. Pessin Delores A. Seeber Robert Temple 36 | MJFF ANNUAL REPORT 2009 Donor Listing

F O R P ARKINSON’S RESEAR CH

In 2009, over 1,000 dedicated Team Fox members collectively raised nearly $3 million to support The Michael J. Fox Foundation’s high-impact research programs. Whether they flip pancakes, start a golf tournament, hold a yard sale or run a marathon, these passionate and creative people all over the world form an unstoppable team that keeps finding more ways to help advance the Foundation’s vital work — bringing us all closer to new treatments and a cure for Parkinson’s disease.

$50,000 or more Catherine Dumoff University of Virginia Kasey Jaffe Susan Bilotta Rally for Parkinson’s Tennis 5th Annual Pancakes for Parkinson’s Party and Silent Auction Tournament Tips for Parkinson’s The Wistran Family Lori Jawitz Michael Costa Eagle Bridge Foundation 3rd Annual North Shore Walk for Unity Walk Sigma Chi EBF Golf Weekend Parkinson’s Disease The War on Parkinson’s Warsaw Center Softball Game Tracey Earl Elizabeth Woodbury Jog for Jim Buckles and Spurs Gala Annual Spring & Summer Style Show Susan Kauffman Catherine Keane Kickin’ Parkinson’s One Lap at a Time The Epstein Family $5,000 or more Boston Marathon Mary Anne Ostrenga Epstein Family Pancakes for Andrew Allen Brad Kear and Lois Kear Garden Walk & Sunset Reception Parkinson’s Spin for a Cure Party for Parkinson’s JoAnn Runk Michael Feinsod Laurie Allen Diane Kinsey “Music for Parkinson’s” Benefit City to the Sand 100 Mile Ride Reach Out Hearts Walk With Mary Concert Nicholas Frasso Alpha Tau Omega Steve Klassen Wilkins Media Company Help Hook The Cure Striped Bass 3rd Annual Charity Chili Cook-Off Fundraising Letter Campaign Polo for Parkinson’s Derby John Antonini Tavia Kowalchuk The Woods Family Gene Gaunt Austin Triathlon Baltimore Half Marathon The New England Parkinson’s Ride Boston Marathon Al and Beth Levine Doug Gigliotti Jan Bogner Hockey and Triathlon Events $25,000 or more Steak Fry Put the Fire Out for Parkinson’s Jon Maier Delaware Pancakes Committee Jayne Godfrey Brendan Callahan Mighty Hamptons Triathlon 1st Annual DE Pancakes for The Bluegill Benefit Boston Marathon Parkinson’s Gary Marks Yonina Gomberg John Carter Patriot Golf Tournament David Eger NYC Half Marathon Racing the Planet: The Gobi March 7th Annual Music for Parkinson’s Erin Raitt and Scott Martineau Team Gordon Jennifer Chadwick Research Concert ESi Ironman 70.3 Augusta Providence Rhode Races Tiptoe through Tulips The Greif Family Alyssa Johnson and Barry Cohen Steve Miller 5th Annual Friends of Parkinson’s Junior Hollywood Radio and Wet Dogs Calendar / NYC and Boston Marathon Twilight Golf Outing Television Society JHRTS Holiday Party Boston Marathons Eric Neiman Larry Howald Carol Constable Seussical at Tri-Valley Rep Theatre Seven-In-Seven Eugenia Koog Play to Find a Cure for Golf for Parkinson’s Benefit Ohio State University Josephine Poehlmann Parkinson’s Disease Jody Culmone 2nd Annual Pancakes for Parkinson’s 7th Annual Benefit in Memory of Team Fox Fundraiser Gail Oliver Tom Poehlmann Neil Korf Team Fox Fundraiser Dance for a Cure Mrs. Mo Memorial Golf Tournament Rucker’s Candy Ciao Parkinson’s Stephanie Paddock LCPDA Golf Classic Fundraiser Pinky’s Passion for a Parkinson’s Cure Pinky’s Passion for Fashion The Deery Family NYC Triathlon $10,000 or more Zachary Rau Dick Deery Run/Walk for MSA Michala and Dennis Witas Arrowhead Inn Dic-Wisco Farms Pars for David Diedffenbach Pubbin’ for Parkinson’s Arrowhead Open Golf Classic Parkinson’s Golf Outing Boston Marathon Sarah Rasmussen Skip Bailey Ryan Reynolds Sean Ferrell Team Fox Golf Tournament Coast to Coast for Parkinson’s Team Fox Celebrity Chair Marine Corps Marathon Ken Reichel Research Mara Richards Meg Fisher 50 Marathons Before 50 Marian C. Bell Foundation Peaks for Parkinson’s 1st Annual Pig Roast for Josh Rozbruch P.A.R. for Parkinson’s Golf Event Gary Schmitz Parkinson’s Research Boston Marathon Tim Blair Walkfest ’09 Timothy Fitzgibbons Richard Sanks Antarctica Marathon Kyle Shackleton and Drew Shackleton Boston Marathon Ironman Germany Peter Bleiberg Chicago Marathon Debby and Lou Flancbaum Amiel Sawdaye Boston Marathon Sean Slaughter Pars for Parkinson’s The New England Parkinson’s Ride Rosemary Beach Foundation, Inc. Team Fox Tennis Tournament Ryan Grant Kathi Sawka The Jim DelMauro Rosemary Michael Spanier Pints for Parkinson’s Disease Boston Marathon Beach Run Fundraiser Chicago Marathon Team Meem David Dorsey Team N2Tri Oliver Holler Utica Boilermaker Hilton Inn at Penn Reception To The Future: Transcontinental Longhorn Ironman 70.3 David Teitelbaum and Auction Mission Knight-Teitelbaum Wedding Donor Listing MJFF AnnuAL REPORT 2009 | 37

ING NYC Marathon

Team Fox’s growing marathon program was honored to be included again as an official charity partner in the 2009 ING NYC Marathon. 220 runners from four countries and 21 U.S. states put one foot in front of the other for 26.2 miles to raise over $857,000 for The Michael J. Fox Foundation’s research toward a cure.

Sarah Washerstein $50,000 or more Jen Anderson Noah Lucas Business 1st Annual Dance Party For Amar Kuchinad Adrienne Baranowicz Michael Lyons Amberleigh Thetford Parkinson’s Alex Beck Naz Majidi Lucy Evans Ulmer $25,000 or more Gretchen Weber Rebecca Bennett Jason Mang David Weber Ironman Michael Dubin Eric Bland Laura Manofsky Abby White Eileen Werndorfer Veronique Enos Clayre Brown Joseph McDonnell Margaret Whiting Brookfield Parkinson Run/Walk Tim Reid Jennifer Browne Pamela McIlvaine Peter Wilson Tim Wheeler Tony Carbone Andrew McLean Murray John Wilson Cole & Friends: An Elegant Evening $10,000 or more Yves Chabot Vincent Carrotozzolo Mike McPartland Ronald Wong Kathy Zweifel Andrea Castillo Deborah Meyer Aileen Wong Party for Parkinson’s Gregory Conen Dan Meador James Chmiel Kristine Miller Jean Yee Doreen Clifford Gwen Miller Patti Yoon $2,500 or more Nike, Inc. William Connelly Brian Monk John Zainea Steve Alten Kenneth Olson Team Fox Fundraiser Rebecca Corso Annick Mullen Kevin and Colleen Schirf $1,000 or more Cintra Bentley Blair Coulson Kristin Murray Danielle Andreasi Chicago Marathon $5,000 or more Dana Coyle Keith Nelson Daryl Austin Benjamin Bernstein Anne Elizabeth Baker Tim Crowley Mariel O’Brien Jason Bennett NYC Half Marathon Alex Bird Dayna De Simone Daniel O’Reilly The Coffee Bean & Bryan Blackorby Gary Cervantes Kimberly Dewalt Lauren Ostendorf Tea Leaf ING Atlanta Half Marathon Steve Denker Simon Esposito Caitlin Peters Jennifer D’Aoust Philip Bloom Jeremiah Driansky Scott Fahey Gail Peters Jamin Davies Black Bear Triathlon Kris Dworkoski McKee Falk Gina Pham Joey Davis Michael Bologna Patrick Egan John Fitzmaurice Rebecca Philps Steve Day Chicago Marathon Lauren Estabrook Robin Flanz Nancy Polstein Timothy Diamond Beth Buzza Ahmed Fahim Chris Grannan Pat Price Thomas Donahue Scott Tinley’s Adventures Road Kurt Fielder Sarah Hansen Andy Renton Phil Evans Triathlon Terence Flannigan Trisha Hanson Siobhan Roberts Bruce Fina The Campanelli Family Ronald Garriques Caitlin Harrington Joao Rodrigues Daniel Gercke Campanelli’s Walk for Parkinson’s Shannon Goff Bethany Hoffman Paul Roer Andrew Gordon Greg Carollo Randy Greben Rusty Holzer Maren Rosen Wendy Grider Chicago Marathon Andy Hunt Lori Hongach Susie Rosenthal Jeremy Heckerling Lisa Clark Christine Kevan Anders Hyde JP Rutigliano Karen Janos Boston Marathon Ken Kubota Roger Imhof Susan Ryan Christine Leslie Janet Clough Gayle Proctor Richard Jones Lauren Rybas Alissa Lifshitz Team Fox 5 Mile Walk Barbara Etzel and Jonathan Kaida Emily Sarokhan Matthew MacGregor Rob Basch David D’Arcy Kari Keane Karin Sawyer Leslie McBeth North Shore Century Bike Ride Erin Robbins Michael Kelly Rob Scheifley Katherine McDonald David Sack Lisa de Lusignan Jennie Kelly Gwen Schroeder Brian McManus Conchman Triathlon Lorri and Terry Scovill Julie King Karen Segall Patty O’Connell Nina Tringali Larry Frank Shawn Kingsley Jennifer Senske Kevin O’Connor 37th Annual California 10 Sally Washburn Scott Kingsley Jennifer Shea Joanna Pedersen Jamie Franz Stephanie Wenning and Nathan Kirk Nicole Sieffert-Fink Lauren Wenning Jason Roer Chicago Marathon Jesse Kraus Corrin Silver Matt Wilbur Daniela Rosello Laura Gryniewich and Lorraine Rachel Kreisman Phil Sosnow Alex Rosello Gryniewich Donna Williams Jon Kully Stephen Stowe Erin Sheard Under Armour Baltimore Running $2,500 or more Michele Kustera Frank Stramiello Festival Neil Thomson Liza Abad Shawn Leo Jacquelyn Strycker David Wilburn Deborah Hagel David Levine Michael Sunwoo Team Fox Dinner Party Fahad Ahmed Heather Allerdice-Gerow Jeremy Levy Jennifer Szpila Hal Halvorsen James Lin John and Susie Teal Boston Marathon Nora Ammar Erin Loebner The Sauder School of continued on page 38 38 | MJFF ANNUAL REPORT 2009 Donor Listing

(continued from page 37) F O R P ARKINSON’S RESEAR CH

Patrick Hatton Kari Travis Inci Ertan Lisa Jay Chicago Marathon Boston Marathon Dinner & Cooking Class Spectrum- Fall Dance Lori Hes Colleen Wuebben Ian Fagan Concert at Laguna More Marathon Wuebben Family Skate-a-Thon NYC Half Marathon Beach High School Brandy Fain Netzer Jennifer Johns Jeffrey Joseph $1,000 or more Fireworks for Fox ING Half Marathon Boston Marathon Maureen Ashdown Dani Farber Tara Jay Johnson Natalie Karp Pocket Change 4 Parkinson’s Canyon Ranch Group Trips NYC Half Marathon The Richard L. Johnson Berkeley County Parkinson’s Memorial Golf Tournament Miranda Feldmann Mount Allison University Support Group Pancakes for Parkinson’s Silly Spooky Movie Nights Brad Kear Bonanza and Softball Tournament Multiple Marathons Christine Finan Jillian Libenson Richard Broughton 1st Annual Nona Libenson 5K/10K NYC Half Marathon Mary Kelly The Annual OBX CruZ for the Cure of Team Fox Athlete Linda Lyle Parkinson’s Disease Morgan Fixel Pay Forward for Parkinson’s Team Fox Fundraiser James Knuckles Jessica Brown Chicago Marathon Chaya Mallavaram Capital of Texas Triathlon Hailey Flynn and Robin Lee Memorial Gifts NYC Half Marathon Jeffrey LaGrange Sarah Bunn Board of Education Jason Matter “Detoxify Your Life” Seminar Linda Foresha Dress Down Day Triple Bypass Bike Ride Pirouettes for Parkinson’s Lou Bushinsky Tracy Lehnecker Jill Matter Chicago Marathon Sheldon Garfinkle Medicus Foundation NYC Half Marathon Triple Bypass Bike Ride Grainne Byrne Fundraising Dustin Matthews NYC Half Marathon Helen Gerry Brian Levy Purse Sales Hacker’s Cup Golf Tournament Bonnie Cha NYC Half Marathon Robin Maxcy NYC Half Marathon Alan Gettis Michael Lewis Philadelphia Marathon Boston Marathon Vicky Clark Honor Gifts Clent Mericle Sale for a Cure Mark Gherty Peter Liberto American Birkebeiner Hit the Road Jack 5K Run/Walk Ken Clary Friends Helping Friends Amy Miller WhistleStop Marathon Jacqueline Gibbons Jennifer Love Hartford Half Marathon Twin Cities Marathon Jennifer Cogan Pancakes for Parkinson’s The Monusky Family Philadelphia Marathon Jill Goldenziel Nate Lukas Boston Half Marathon 2009 “60 for 60” Campaign for Eileen Colon More than Words: Parkinson’s Disease Research The Army of Change Eugene Gurkoff A Benefit Concert Team Fox Fundraiser Kevin Moss Katie Congdon Madison Lyleroehr South Florida Team Fox Scuba Dive Willow Tree Half Marathon Sandra Haas Vocal Performances NYC Half Marathon and CD Proceeds Rosemary Pepe John Cuccinello Party to End Parkinson’s Jarden Westchester Triathlon Diana Hadden Edward Macdonald and Cincinnati Flying Nikita Romanoff Jennifer Porter Laura Dalle Pazze Pig Marathon NYC Half Marathon Popcorn for Parkinson’s Warrior Dash The Hanna Family Chris Magoon and Colette Porcelli Lettieri Stella Darby Inn at Quogue Fashion Show Hanna Family Legacy Katie Magoon Liversedge Half Marathon Providence Rhode Race Gerard Hayes Kim Ready Jeffrey Davis Cowtown Ultra Marathon NYC Half Marathon Lisa and Branko Maric Team Fox Athlete Joint Birthday Party Adam Hegge Samuel Ross Michelle De Luca Marine Corps Marathon Pull for Parkinson’s Theresa Marran NYC Half Marathon Team Fox Dessert Buffet Chad Henson Running for Papa Robert Denlow Dallas White Rock Mark Mason Nashville Country Music Marathon Boston Marathon Marathon Kona Ironman Lori Saviers Meghann Dials Kieran Hughes Cassandra Mastrianni 10 Mountains 10 Years: Illinois Marathon A Quest for the Cure Special Occasion Gifts Pizza for Parkinson’s and The Dobrez Family Day of Enchantment Larry Ice Trey Sebus Team Fox Fundraiser Chicago Marathon Parkinson’s Awareness Soania Mathur Greg Drumheller Building Events Team Fox Fundraiser Steve Spencer The Jerry G. Barnhart Lenore Imhof Sean McDonald “You Can’t Take It With You” Memorial Poker Tournament Play Proceeds Jarden Westchester Cedar Springs Circle Annual Martin Eldred Triathlon Crawfish Boil Brian Thorne Humpy’s Classic Marathon 2nd Annual Friends of Jordan Isenstadt Sasha Mobley Team Fox Holiday Party Elaine Ellis NYC Half Marathon Healdsburg Half Marathon Premier Jewelry Show Karen Janos Amanda Neal Team Fox Fundraiser Tour of Anchorage Donor Listing MJFF AnnuAL REPORT 2009 | 39

2009 Community Fundrasiers

Mary Ann Neilson Mark and Mary Sue Taylor 2nd Annual Keystone State Kroger cards distribution The Foundation is grateful to the following Corvette Club Poker Run Thomas Tedesco donors for their generous efforts to Mike O’Brien and Tom O’Brien Team Fox Athlete raise funds and awareness for MJFF and Ironman St. George Emily Twiss Parkinson’s research through community Patti Olszewski Austin Half Marathon fundraising events. Chicago Rock ‘n’ Roll Andrew Vale Half Marathon Marine Corps Marathon Miranda Owens Garth Wakeford $25,000 or more Phoenix Rock ‘n’ Roll Marathon NYC Half Marathon 23andMe Gaetano Parrinello Jason Warner Michael Cotoia NYC Half Marathon Gordon Ferguson Yackle’s 10K Run Jeanette Pena Against Parkinson’s $10,000 or more ITSource Technology Chicago Rock ‘n’ Roll Renee Wegrzyn Half Marathon NYC Half Marathon Sydney Goldstein Chris Piper Meg Weidner $5,000 or more Chris Piper’s Grand Loop Cupcake Mission Mountain Biking Adventure ALL TRI, Inc. Diana Wiesner CSRA PD Support Group Walkathon We have made Allison Platt Capital City Half Marathon Party for Parkinson’s Preston L. Lowe a concerted Brianne Yantz Larissa Raze NYC Half Marathon Parkinson’s Support Group of effort to Team Fox Fundraiser Rochester NY, Inc. Jonah Yesowitz accurately Debbie Shough Michael Redfern Kid’s Carnival of Caring Multiple events Summit County Parkinson’s Support Group list all donors Damon Zaleski Jeannette Reiff of significant Chicago Marathon $2,500 or more Pedal for Parkinson’s contributions Robert Benjamin/Light of Day Foundation Mary Rich in 2009. Team Fox Wristbands California Jurisdictional Convention Staci Roberts Illinois Shotokan Booster Club Team Fox Athlete JTB International Ltd. If your name is Beth Salyers Megan Layer Napa to Sonoma Wine Rocking For Parkinson’s Disease misspelled or Country Half-Marathon Research Foundation, Inc. missing from Lenni Sand Brad Schenker Bar Mitzvah this report, Team Fox Fundraiser Sandy Smith please accept Reggie Scarpa Hartford Half Marathon $1,000 or more our apology and Nikki Schiro Aeroquip Credit Union email the correct NYC Half Marathon Judith Binder information to Molly Scott Karen deGraaf donations@ Molly’s Mission for Grandpa Stephen E. Farris michaeljfox.org. Kara Sessums Federal Aviation Administration NYC Half Marathon Mark Friedman Enzo Simone Ariel Linden The Army of Change Hamden High School Hockey Brad Smith Alumni Association NYC Half Marathon I Do Foundation April Socci Micanopy Area Chamber of Commerce NYC Half Marathon MissionFish Lee Sommers Eileen O’Neill Team Fox Fundraiser Scars Into Stars Charity Rik Spier Mini Marathon 5K Walk/Run Anne-Cecilie Engell Speyer and Rob Speyer Arun Subramaniyan Tokio Marine Management, Inc. Walk for Research to Wells Fargo Community Support Campagin Fight Parkinson’s Westlake Golf and Country Club Jacqueline Talarico Jewelry Sales 40 | MJFF ANNUAL REPORT 2009 Financial Highlights

6 MJFF’s place 2009 Financial Highlights on Worth.com’s 2009 Elite List of the 10 most fiscally responsible charities The Michael J. Fox Foundation believes donors have a right to look for measurable returns on their investment. We operate according to best practices and remain accountable to our donors and the Parkinson’s community for ensuring maximum effectiveness. Our leadership was recruited from the worlds of finance, management and neuroscience, bringing strategic skills, scientific and MJFF Efficiency 2000–2009 operational expertise, and an investment professional’s sensibility to the management of the Foundation.

n We constantly monitor costs to maximize the value of donations. Research Program Activities 86% Since inception, 86 cents of every dollar we’ve spent has gone Administration 3% straight to our research programs effort.

Fundraising 11% n We are outcomes-focused, tying grant payments to the achievement of specific milestones, troubleshooting challenges if Financial Highlights MJFF ANNUAL REPORt 2009 | 41

“Donors to The Michael J. Fox Foundation for Parkinson’s Research have provided funds used to expedite grant processes, establish benchmarks for progress, apply continuous evaluation practices, and invest in a portfolio of promising research initiatives simultaneously... helping to reduce the overall risk of research investments, create new incentives for scientists and change the culture and expectations around medical research.” Issue Brief: Investing in Medical Research, Arabella Philanthropic Investment Advisors (2010) they arise, and halting funding if the science stalls. And we demand the same accountability and transparency of ourselves as we do of our awardees. n We deliberately have no endowment, because we believe that to speed a cure for Parkinson’s disease, our capital needs to get into scientists’ hands as quickly as possible — not sit in an endowment Research Allocation 2009 or reserve. MJFF ended 2009 closing in on the $200-million mark in research Clinical Research 49% funded since inception. Ultimately, though, we measure our impact not in terms of dollars spent, but in terms of scientific solutions that produce tangible improvements in patients’ lives. Transforming Discoveries Into Targets Translational Research 41%

2009 financial highlights follow. Full audited financials and our most New Tools and Technologies recent IRS Form 990s are available at michaeljfox.org. Understanding Disease 10%

Growing Investments in PD Research 2001-2009

45 $ 39 40

35 $ 33

30

25 $ 24 $ 24

20 $ 17 $ 15 15 $ 14 $ 12 10

5 $ 4

0 2001 2002 2003 2004 2005 2006 2007 2008 2009

Dollar amounts in millions. Does not include 2001 R21 awards in partnership with NIH. 42 | MJFF ANNUAL REPORT 2009 Financial Highlights

The Michael J. Fox Foundation for Parkinson’s Research Consolidated Statements of Financial Position

As of December 31, 2009 2008 Assets Cash, cash equivalents and investments $ 33,422,684 $ 30,962,536 Contributions receivable, net 35,401,415 26,762,424 Prepaid expenses and other current assets 156,687 162,958 Security deposits 33,061 33,061 Inventory 28,036 Property and equipment, net 278,893 388,610 Total assets $ 69,320,776 $ 58,309,589

Liabilities and Net Assets Liabilities: Accounts payable and accrued expenses $ 1,713,780 $ 1,066,594 Grants payable, net 42,161,174 38,882,706 Loan payable 1,000,196 1,000,196 Interest payable 59,511 13,089 Deferred rent 358,114 367,192 Total liabilities 45,292,775 41,329,777

Net Assets: Unrestricted 2,345,986 (5,516,236) Temporarily restricted 21,682,015 22,496,048 Total net assets 24,028,001 16,979,812 Total liabilities and net assets $ 69,320,776 $ 53,309,589

Note: Investments are highly liquid. Financial Highlights MJFF ANNUAL REPORt 2009 | 43

The Michael J. Fox Foundation for Parkinson’s Research Consolidated Statements of Activities

Year Ended December 31, 2009 2008 Public support and revenue: Contributions $ 45,433,897 $ 35,335,877 Special events 5,825,680 6,741,990 Investment income 119,440 662,655 Miscellaneous income 37,425 25,682 Total public support and revenue 51,416,442 42,766,204

Expenses: Program services 39,153,137 36,236,785 Management and general 1,263,737 1,093,996 Fund-raising 3,951,379 4,130,806 Total expenses 44,368,253 41,461,587

Change in net assets 7,048,189 1,304,617 Net assets, beginning of year 16,979,812 15,675,195 Net assets, end of year $ 24,028,001 $ 16,979,812

Todd Sherer (left), vice president, Research Programs, MJFF, and Andrew Singleton of the National Institute of Aging (NIH) and MJFF’s Executive Scientific Advisory Board at the Investigators’ Meeting for the Parkinson’s Progression Markers Initiative (PPMI) study launching in 2010. 44 | MJFF ANNUAL REPORT

Progress: Photo and Illustration Credits The 2009 Annual Report of The Michael J. Fox On the cover lost profits, arising out of the use Pages 12–13 Dopamine neurons and their death of this CCDB website, even if the Photo of Angela Cenci-Nilsson Foundation for Parkinson’s in Parkinson’s disease. At left and University of California has been courtesy of Lund University, Sweden. Research was published center, cell death in the substantia advised of the possibility of such Table depicts data produced in the nigra, the brain region affected in damage. in June 2010. It is laboratory of M.A. Cenci at Lund PD. At right, a dopamine neuron available in PDF format The CCDB website provided herein University, Sweden. expressing LRRK2. LRRK2 mutations is on an “as is” basis, and the at www.michaeljfox.org. are now believed to be the most University of California has no Structure of serotonin copyright common genetic contribution to PD. obligation to provide maintenance, 2005–2007 Karl Harrison. Images courtesy of Robert Burke, PhD, support, updates, enhancements, Page 14 Katie Hood Columbia University (left and center) or modifications. The University of Photo of Simon Lewis courtesy of the CEO and Mark Cookson, PhD, National California makes no representations University of Sydney, Australia. Institute of Aging, National Institutes and extends no warranties of any of Health (right). Michael J. Fox kind, either implied or express, Pages 16–17 Founder Page 3 including, but not limited to, the Zinc Finger Nuclease schematic implied warranties of merchantability Deborah W. Brooks Photo of Katie Hood: courtesy of Sigma-Aldrich. Getty Images/Michael Buckner. or fitness for a particular purpose, or Photo courtesy of Weill Cornell Co-Founder Photos of Michael J. Fox and Debi that the use of the CCDB website will Medical College. Brooks: WireImage/Kevin Perry. not infringe any patent, trademark, or other rights. Editor: Pages 20–21 Holly Barkhymer Page 4 Page 5 Photos 1, 2, 5, 8, 14: WireImage/ Associate Director, Pre-clinical model cerebellum LRRK2 images courtesy of Mark Kevin Mazur. Communications copyright 2002–2007, The Regents Photos 3, 9, 12, 17: Ann Billingsley. of the University of California. All Cookson. Photo 4 courtesy of Amar Kuchinad. Writers: Rights Reserved. Permission to use, Page 6 Photo 6 courtesy of Drew and Kyle Holly Barkhymer copy, modify, and distribute any part Dopamine neuron images courtesy of Shackleton. Katrina Kahl of the Cell Centered Database (CCDB) John Sinclair. Photos 7, 11, 13: Getty Images/ Associate Director, website for educational, research, and Michael Buckner. Communications non-profit purposes, without fee, and Pages 8–9 Photo 10: Tommy Sandler without a written agreement is hereby Designer: Dopamine schematic courtesy of Photo 16: Elena Olivo. Susan Shaw granted, provided that the above Dr. Paul Greengard, The Rockefeller copyright notice, this paragraph, and University, with the technical Page 40 the following three paragraphs appear assistance of Elisabeth Griggs. Elena Olivo. in all copies. The Michael J. Fox Foundation is a Photo courtesy of Vanderbilt Page 43 501(c)3 nonprofit organization. Those desiring to incorporate this Medical Center. Elena Olivo. CCDB website into commercial © 2010 The Michael J. Fox products or use for commercial Crystal structure of G-CSF as Inside back cover Foundation for Parkinson’s Research purposes should contact Dr. Maryann published in the Protein Data Bank Yeast cells expressing human Martone at 858-822-0745 and (PDB: 1RHG), public domain. Created alpha-synuclein tagged with a Technology Transfer and Intellectual from PDB 1RHG and rendered by green-fluorescent protein courtesy of Property Services, University of Ramin Herati using Pymol, March Susan Lindquist, Whitehead Institute California, San Diego, 9500 Gilman 10, 2007. for Biomedical Research/Aaron Gitler, Drive, La Jolla, CA 92093-0910, Pages 10–11 University of Pennsylvania. Phone: (857) 534-5815, Fax: (858) 534-7345, email: [email protected]. Photo of Marina Emborg courtesy of the University of Wisconsin, Madison. In no event shall the University of California be liable to any party for Photo of Wolfgang Oertel courtesy of direct, indirect, special, incidental, Philipps University Marburg, Germany. or consequential damages, including Photo of nicotine patch: Getty Images.

The Michael J. Fox Foundation gratefully acknowledges Bulkley Dunton for donating the high-quality McCoy Silk Cover and Text paper on which this annual report was printed, and Yes Press for printing this report below cost. Our gratitude to Hearst Corporation for facilitating both donations.

Board of Directors Founders’ Council Scientific Advisory Board George E. Prescott Lonnie and Muhammad Ali Chairman Steven A. Cohen Gene Johnson, PhD John A. Griffin David Golub Chief Scientific Advisor* Andrew S. Grove Vice Chairman Jeffrey Katzenberg Irene Hegeman Richard, MD Holly S. Andersen, MD Nora McAniff Senior Medical Advisor* Eva Andersson-Dubin, MD Donna E. Shalala, PhD Alberto Ascherio, MD, DrPH Jon Brooks Erwan Bezard, PhD Barry J. Cohen Anders Björklund, MD, PhD Donny Deutsch Leadership Council Susan Bressman, MD* David Einhorn Robert E. Burke, MD Karen Finerman Scott Schefrin Angela Cenci-Nilsson, MD, PhD Nelle Fortenberry Chairman Marie-Françoise Chesselet, MD, PhD Michael J. Fox Claire Capello P. Jeffrey Conn, PhD Albert B. Glickman Dev Chodry Mark Cookson, PhD* Mark L. Hart III Sonya Chodry David Eidelberg, MD Skip Irving Anne-Cecilie Engell Speyer Matthew Farrer, PhD Kathleen Kennedy Richard Fitzgerald Charles (Chip) Gerfen, PhD Morton M. Kondracke Lee Fixel J. Timothy Greenamyre, MD, PhD Edwin A. Levy Sean Goodrich Franz F. Hefti, PhD Marc S. Lipschultz Amar Kuchinad Etienne C. Hirsch, PhD Kenneth Olden, PhD, ScD Joella Lykouretzos Oleh Hornykiewicz, MD Douglas I. Ostrover Ole Isacson, MD (Dr Med Sci) Tracy Pollan Joseph Jankovic, MD* Ryan Reynolds Patient Council Jennifer Johnston, PhD Frederick E. Rowe Jeffrey H. Kordower, PhD Lily Safra Eugenia Brin J. William Langston, MD Curtis Schenker Carey Christensen Frans Olof (Olle) Lindvall, MD, PhD Woody Shackleton David Eger, PhD Andres Lozano, MD, PhD Fred G. Weiss David Iverson Soania Mathur, BSc, MD, CCFP Kenneth Marek, MD Thomas A. Picone, PhD Eldad Melamed, MD Richard Rothenberg Kalpana Merchant, PhD W.N. “Bill” Wilkins C. Warren Olanow, MD Bernard M. Ravina, MD, MSCE Peter H. Reinhart, PhD Ira Shoulson, MD Andrew Singleton, PhD * David G. Standaert, MD, PhD Dennis A. Steindler, PhD Caroline Tanner, MD, PhD David Weiner, MD* Michael Zigmond, PhD

* Executive Committee

4 | MJFF ANNUAL REPORT 2009 year in photos

Church Street Station P.O. Box 780 New York, NY 10008-0780 (800) 708-7644 www.michaeljfox.org

Progress